{{medical}}
{{noteTA
|G1=医学
|1=zh-hans:吸烟;zh-hk:吸煙;zh-tw:吸菸;
|2=zh-cn:乳腺癌; zh-hk:乳癌;
|3=zh-cn:通过; zh-tw:透過; zh-hk:通過;
|4=zh-hans:二手烟;zh-hk:二手煙;zh-tw:二手菸;
}}
{{About|肺部癌症|其他肺部肿瘤|肺部肿瘤}}
{{Infobox medical condition (new)
| name            = 肺癌
| synonyms        = Lung carcinoma
| image           = LungCACXR.PNG
| caption         = {{link-en|胸部X光片|Chest radiograph}}（胸片）显示出肺部肿瘤（箭头所指处）。
| field           = [[肿瘤学|肿瘤学]]
| symptoms        = 咳嗽（包含[[咳血|咳嗽咳出血]]）、[[體重減輕|體重減輕]]、[[呼吸短促|呼吸短促]]、各種[[胸痛|胸痛]]<ref name="Harrison"/>
| complications   = 
| onset           = ~70 歲<ref name="SEER"/>
| duration        = 
| types           = [[小细胞癌|小细胞癌]]（SCLC）、{{tsl|en|non-small-cell lung carcinoma|非小細胞癌}}（NSCLC）<ref name=NCI2016Pt/>
| causes          = 
| risks  =[[吸菸|吸菸]]、[[遗传学|遺傳因子]]、[[氡|氡]]氣、[[石棉|石棉]]、[[空氣污染|空氣污染]]<ref name="MurrayNadel52"/><ref name="O'Reilly"/>
| diagnosis       = [[醫學影像|醫學影像]]、[[活體組織切片|活體組織切片]]<ref name="Holland-Frei78"/><ref name="Merck"/>
| differential    = 
| prevention      = 
| treatment       = [[外科學|外科手術]]、[[化学疗法|化学疗法]]、[[放射線療法|放射線療法]]<ref name="Merck"/>
| medication      = 
| prognosis       = [[五年存活率|五年存活率]] 17.4%（美國）<ref name="SEER"/>
| frequency       = 330萬（2015年）<!-- prevalence --><ref name="GBD2015Pre">{{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=2016-10-08|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}}</ref>
| deaths   = 170萬（2015年）<ref name=GBD2015De>{{cite journal|last1=GBD 2015 Mortality and Causes of Death|first1=Collaborators.|title=Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=2016-10-08|volume=388|issue=10053|pages=1459–1544|pmid=27733281|doi=10.1016/S0140-6736(16)31012-1|pmc=5388903}}</ref>
}}
<!-- Definition and symptoms -->
'''肺癌'''（{{lang-en|Lung cancer}}<ref name="Merck">{{cite web | title=Lung Carcinoma: Tumors of the Lungs | publisher=Merck Manual Professional Edition, Online edition | url=http://www.merck.com/mmpe/sec05/ch062/ch062b.html#sec05-ch062-ch062b-1405 | accessdate=2007-08-15 | deadurl=no | archiveurl=https://web.archive.org/web/20070816142739/http://www.merck.com/mmpe/sec05/ch062/ch062b.html#sec05-ch062-ch062b-1405 | archivedate=2007-08-16}}</ref>）是惡性的[[肺部肿瘤|肺部肿瘤]]，肇因於[[肺|肺部]]組織细胞不受控制地{{tsl|en|cell growth|細胞生長|生長}}<ref>{{cite web|title=Non-Small Cell Lung Cancer Treatment –Patient Version (PDQ®)|url=http://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq|website=NCI|accessdate=2016-03-05|date=2015-05-12|deadurl=no|archiveurl=https://web.archive.org/web/20160229172247/http://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq|archivedate=2016-02-29}}</ref>。如不治疗，[[贅生物|肿瘤细胞]]會[[遠端轉移|转移]]至鄰近組織或身體的其他地方<ref>{{cite book | vauthors = Falk S, Williams C | title=Lung Cancer—the facts | edition=3rd | chapter=Chapter 1 | pages=3–4 | publisher=Oxford University Press | year=2010 | isbn=978-0-19-956933-5 }}</ref>。肺部最常見的原發性[[癌症|惡性腫瘤]]屬於[[癌|上皮癌]]<ref name=WCR2014Chp5.1/>，可粗分為[[小细胞癌|小细胞癌]]（SCLC）和{{tsl|en|non-small-cell lung carcinoma|非小细胞癌}}（NSCLC）<ref name=NCI2016Pt>{{cite web|title=Lung Cancer—Patient Version|url=http://www.cancer.gov/types/lung|website=NCI|accessdate=2016-03-05|deadurl=no|archiveurl=https://web.archive.org/web/20160309175259/http://www.cancer.gov/types/lung|archivedate=2016-03-09}}</ref>。肺癌最常見的[[症狀|症狀]]有[[咳嗽|咳嗽]]（包括[[咳血|咳血]]）、[[體重下降|体重减轻]]、气短和[[胸痛|胸痛]]<ref name="Harrison">{{cite book | vauthors = Horn L, Lovly CM, Johnson DH | title=Harrison's Principles of Internal Medicine | publisher=McGraw-Hill | veditors = Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J | year=2015 | chapter=Chapter 107: Neoplasms of the lung | edition=19th | isbn=978-0-07-180216-1 }}</ref>。

<!-- Cause and diagnosis -->
大多数（85%）肺癌患者患病的原因为长期[[吸菸|吸菸]]<ref name="MurrayNadel52"/>，然而亦有大约10-15%的患者从不吸菸<ref name="Thun">{{Cite journal  |vauthors=Thun MJ, Hannan LM, Adams-Campbell LL, etal | title=Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies | journal=PLoS Medicine | volume=5 | issue=9 | pages=e185 |date=September 2008 | doi=10.1371/journal.pmed.0050185 | pmid=18788891 | pmc=2531137 }}</ref>。这部分人患上肺癌常是由于[[遗传学|遗传因素]]和吸入[[氡|氡氣]]、[[石棉|石棉]]、[[二手煙|二手煙]]，或其他空气污染物共同导致<ref name="MurrayNadel52">{{cite book | vauthors = Alberg AJ, Brock MV, Samet JM | title=Murray & Nadel's Textbook of Respiratory Medicine | publisher=Saunders Elsevier | year=2016 | chapter=Chapter 52: Epidemiology of lung cancer | edition=6th | isbn=978-1-4557-3383-5 }}</ref><ref name="AUTOREF">{{cite web |url=https://www.ncbi.nlm.nih.gov/books/NBK44324/ |author=Carmona, RH |publisher=U.S. Department of Health and Human Services |title=The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General |date=2006-06-27 |quote=Secondhand smoke exposure causes disease and premature death in children and adults who do not smoke. |deadurl=no |archiveurl=https://web.archive.org/web/20170215064658/https://www.ncbi.nlm.nih.gov/books/NBK44324/ |archivedate=2017-02-15  }} </ref><ref name="O'Reilly">{{cite journal | vauthors = O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ | title = Asbestos-related lung disease | journal = American Family Physician | volume = 75 | issue = 5 | pages = 683–8 | date = March 2007 | pmid = 17375514 | url = http://www.aafp.org/afp/20070301/683.html | archive-url = https://web.archive.org/web/20070929083111/http://www.aafp.org/afp/20070301/683.html | deadurl = no | archive-date = 2007年9月29日 }}</ref><ref name="AUTOREF1">{{Cite journal |url=http://monographs.iarc.fr/ENG/Monographs/vol83/mono83.pdf |format=PDF |publisher=WHO International Agency for Research on Cancer |title=Tobacco Smoke and Involuntary Smoking |journal=IARC Monographs on the Evaluation of Carcinogenic Risks to Humans |volume=83 |year=2004 |quote=There is sufficient evidence that involuntary smoking (exposure to secondhand or 'environmental' tobacco smoke) causes lung cancer in humans. ... Involuntary smoking (exposure to secondhand or 'environmental' tobacco smoke) is carcinogenic to humans (Group 1). |deadurl=no |archiveurl=https://web.archive.org/web/20150813204458/http://monographs.iarc.fr/ENG/Monographs/vol83/mono83.pdf |archivedate=2015-08-13  }}</ref>。肺癌在{{link-en|胸片|Chest radiograph}}或[[X射线计算机断层成像|斷層掃描]]（CT）中可见<ref name="Merck"/>，并可通过{{link-en|支气管镜|Bronchoscopy}}或CT引导下进行[[活體組織切片|活检]]确诊<ref name="Holland-Frei78">{{cite book | vauthors=Lu C, Onn A, Vaporciyan AA, etal | title=Holland-Frei Cancer Medicine | edition=8th | chapter=Chapter 78: Cancer of the Lung | publisher=People's Medical Publishing House | year=2010 |isbn=978-1-60795-014-1 }}</ref><ref name="Collins">{{cite journal | vauthors = Collins LG, Haines C, Perkel R, Enck RE | title = Lung cancer: diagnosis and management | journal = American Family Physician | volume = 75 | issue = 1 | pages = 56–63 | date = January 2007 | pmid = 17225705 | url = http://www.aafp.org/afp/20070101/56.html | archive-url = https://web.archive.org/web/20070929104510/http://www.aafp.org/afp/20070101/56.html | deadurl = no | archive-date = 2007年9月29日 }}</ref>。

<!-- Prevention and treatment -->
避開汙染物等風險因子為最主要的預防方式<ref name=NCI2015Pre>{{cite web|title=Lung Cancer Prevention–Patient Version (PDQ®)|url=http://www.cancer.gov/types/lung/patient/lung-prevention-pdq#section/_12|website=NCI|accessdate=2016-03-05|date=2015-11-04|deadurl=no|archiveurl=https://web.archive.org/web/20160309063009/http://www.cancer.gov/types/lung/patient/lung-prevention-pdq#section/_12|archivedate=2016-03-09}}</ref>。肺癌的治疗和长期疗效取决于[[肺癌分期|类型]]、阶段（转移的程度）和患者的整体健康状况<ref name="Merck"/>。大多數的肺癌無法治癒<ref name=NCI2016Pt/>，常見治療方式有[[外科学|外科手術]]、[[化疗|化疗]]和[[放疗|放疗]]<ref name="Merck"/>。非小细胞肺癌有时采用手术治疗，而小细胞肺癌（SCLC）通常对化疗和放疗的效果佳<ref>{{cite book | vauthors = Chapman S, Robinson G, Stradling J, West S, Wrightson J | title=Oxford Handbook of Respiratory Medicine | edition=3rd | chapter=Chapter 31 | page=284 | publisher=Oxford University Press | year=2014 | isbn=978-0-19-870386-0 }}</ref>。

<!-- Epidemiology -->
在2012年，全球約有180萬人新罹患肺癌，並導致160萬人死亡<ref name=WCR2014Chp5.1>{{cite book|title=World Cancer Report 2014|date=2014|publisher=World Health Organization|isbn=92-832-0429-8|pages=Chapter 5.1}}</ref>。肺癌是男性常見的癌症致死病因，在女性則僅次於[[乳癌|乳癌]]，列名第二<ref name=WCR2014Epi>{{cite book|title=World Cancer Report 2014|date=2014|publisher=World Health Organization|isbn=92-832-0429-8|pages=Chapter 1.1}}</ref>。肺癌最常於70歲上下診斷<ref name="SEER"/>。在美国，总体而言患者在确诊为肺癌之後，有17.4%的人[[五年存活率|存活时间超过5年]]<ref name="SEER">{{cite web | title=Surveillance, Epidemiology and End Results Program | url=http://seer.cancer.gov/statfacts/html/lungb.html | website=National Cancer Institute | accessdate=2016-03-05 | deadurl=no | archiveurl=https://web.archive.org/web/20160304031945/http://seer.cancer.gov/statfacts/html/lungb.html | archivedate=2016-03-04 }}</ref>，而这个比例在发展中国家则较低<ref name=Maj2009>{{cite book|last=Majumder|first=Sadhan | name-list-format = vanc |title=Stem cells and cancer|year=2009|publisher=Springer|location=New York|isbn=978-0-387-89611-3|page=193|url=https://books.google.com/books?id=HaErOupWnO0C&pg=PA193|edition=Online-Ausg.|deadurl=no|archiveurl=https://web.archive.org/web/20151018040051/https://books.google.com/books?id=HaErOupWnO0C&pg=PA193|archivedate=2015-10-18}}</ref>。
{{TOC limit|3}}

==臨床表現==
肺癌的臨床表現包含：<ref name="Harrison"/>
* 呼吸道症狀：[[咳嗽|咳嗽]]、[[咳血|咳血]]、[[喘鳴|喘鳴]]，或[[呼吸困难|呼吸困难]]
* 全身性症狀：體重減輕、[[虛弱|虛弱]]、[[发热|发热]]，或{{tsl|en|Nail clubbing|杵狀指}}
* 癌组织压迫临近组织所致的症状：[[胸痛|胸痛]]、{{link-en|骨痛|bone pain}}、{{link-en|上腔静脉阻塞|superior vena cava obstruction}}、[[吞咽困难|吞咽困难]]。

如果肿瘤生长在[[呼吸道|呼吸道]]，那么其可能会阻断气流，造成[[呼吸困难|呼吸困难]]，还可能阻碍呼吸道分泌物的排出，使得分泌物聚积在呼吸道，增加罹患[[肺炎|阻塞性肺炎]]的可能性<ref name="Harrison" />。

不同类型肿瘤，会导致不同的[[腫瘤伴隨症候群|腫瘤伴隨症候群]]。這些與原病灶發生處無關的症狀，常作為初始症狀表現，往往才是肺癌被發現的主因<ref name="Honnorat"/>。肺癌的腫瘤伴隨症狀可能包括[[高血鈣|高血鈣]]、{{tsl|en|syndrome of inappropriate antidiuretic hormone|抗利尿激素分泌异常综合征}}（SIADH，尿液异常浓缩和血液稀释）、異位性[[促腎上腺皮質激素|促腎上腺皮質激素]]（ACTH）分泌、[[Lambert-Eaton_肌無力症候群|Lambert-Eaton 肌無力症候群]]（[[自体免疫疾病|自身抗体]]引起的肌无力）。[[肺|肺尖部]]的肿瘤称为{{link-en|潘科斯特瘤|Pancoast tumor}}可能会侵犯局部[[交感神经系统|交感神经系统]]，导致{{link-en|霍纳氏综合征|Horner's syndrome}}（眼睑低垂和同侧瞳孔缩小），也可能会损伤[[臂神经丛|臂神经丛]]<ref name="Harrison" />。

肺癌的许多症状都不具特异性，如食慾減退、消瘦、發熱和疲乏無力等等<ref name="Holland-Frei78"/>。因此许多患者在出现症状后就医时，癌组织早已从原发部位扩散转移<ref name="ajcc"/>。提示出现癌转移的症状有消瘦、骨痛和神经系统症状（头痛、[[昏厥|昏厥]]、[[惊厥|惊厥]]或四肢无力）<ref name="Harrison"/>。肺癌常見的轉移部位有脑、骨、[[肾上腺|肾上腺]]、对侧肺、肝、[[心包膜|心包膜]]和[[肾脏|肾脏]]<ref name="ajcc"/>。大约10%肺癌患者被确诊时没有临床症状，而是在常规胸片检查时意外发现<ref name="Collins" />。

==病因==
[[Image:Lung_Cancer_Incidece_vers_Cigarette_Consumption.svg|thumb]]
[[File:Cumulative_risk_of_death_from_lung_cancer_1990.svg|thumb]]
細胞的癌變與[[脱氧核糖核酸|DNA]]及表觀遺傳等遺傳信息的突變有關，这些变化会影响细胞的正常功能，包括细胞增殖、程序性细胞死亡（[[细胞凋亡|细胞凋亡]]）和DNA修复。损伤累积的越多，癌症发生的风险就越高<ref name="Holland-Frei8">{{Cite book  |vauthors=Brown KM, Keats JJ, Sekulic A, et al. | title=Holland-Frei Cancer Medicine | publisher=People's Medical Publishing House USA | year=2010 | chapter=Chapter 8 | edition=8th | isbn=978-1-60795-014-1 }}</ref>。

===吸菸===
[[吸菸|吸菸]]是目前为止导致肺癌的主要原因<ref name="MurrayNadel52" />。香菸菸雾中含有至少{{tsl|en|list of cigarette smoke carcinogens|香菸煙霧致癌物質烈表|73种已知的致癌物质}}<ref name="Hecht">{{Cite journal | vauthors = Hecht SS | title=Lung carcinogenesis by tobacco smoke |journal=International Journal of Cancer | volume=131 | issue=12 | pages=2724–2732 | year=2012 | pmid=22945513 | doi=10.1002/ijc.27816 | pmc=3479369 }}</ref>，包括[[苯並［a］芘|苯并芘]]<ref>{{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=199 | chapter=Chapter 5 | isbn=978-1-4377-1781-5 }}</ref>、{{tsl|en|NNK|NNK}}、[[丁二烯|1,3-丁二烯]]，以及[[钋-210|钋-210]]等[[放射性同位素|放射性物質]]<ref name="Hecht" />。以发展中国家在2000年的資料來看，患肺癌死亡的男性中90%是吸菸所致（女性为70%）<ref name="Peto" />。吸菸导致的肺癌患者占了肺癌病人的85%<ref name="Merck" />。

[[被动吸烟|被动吸菸]]（吸二手菸，意为吸入其他吸菸者产生的菸草煙雾）也是导致不吸菸的人患上肺癌的原因。美国<ref name="AUTOREF7">{{cite journal | vauthors =  | title = Health effects of exposure to environmental tobacco smoke. California Environmental Protection Agency | journal = Tobacco Control | volume = 6 | issue = 4 | pages = 346–53 | year = 1997 | pmid = 9583639 | pmc = 1759599 | doi = 10.1136/tc.6.4.346 | url = http://www.druglibrary.org/schaffer/tobacco/caets/ets-main.htm | archive-url = https://web.archive.org/web/20070808045344/http://druglibrary.org/schaffer/tobacco/caets/ets-main.htm | deadurl = no | archive-date = 2007年8月8日 }}</ref><ref>{{cite journal | vauthors =  | title = State-specific prevalence of current cigarette smoking among adults, and policies and attitudes about secondhand smoke--United States, 2000 | journal = MMWR. Morbidity and Mortality Weekly Report | volume = 50 | issue = 49 | pages = 1101–6 | date = December 2001 | pmid = 11794619 | url = https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5049a1.htm | publisher = CDC | authorlink = Centers for Disease Control and Prevention | archive-url = https://web.archive.org/web/20170625143734/https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5049a1.htm | deadurl = no | archive-date = 2017年6月25日 }}</ref><ref name="Alberg">{{cite journal | vauthors = Alberg AJ, Ford JG, Samet JM | title = Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) | journal = Chest | volume = 132 | issue = 3 Suppl | pages = 29S-55S | date = September 2007 | pmid = 17873159 | doi = 10.1378/chest.07-1347 | url = http://chestjournal.chestpubs.org/content/132/3_suppl/29S.long | publisher = American College of Chest Physicians }}</ref> 、欧洲<ref>{{cite journal | vauthors = Jaakkola MS, Jaakkola JJ | title = Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention | journal = The European Respiratory Journal | volume = 28 | issue = 2 | pages = 397–408 | date = August 2006 | pmid = 16880370 | doi = 10.1183/09031936.06.00001306 | url = http://erj.ersjournals.com/content/28/2/397.long | archive-url = https://web.archive.org/web/20130129003845/http://erj.ersjournals.com/content/28/2/397.long | deadurl = no | archive-date = 2013年1月29日 }}</ref>，和英国<ref>{{cite journal | vauthors = Parkin DM | title = 2. Tobacco-attributable cancer burden in the UK in 2010 | journal = British Journal of Cancer | volume = 105 Suppl 2 | issue = Suppl. 2 | pages = S6-S13 | date = December 2011 | pmid = 22158323 | pmc = 3252064 | doi = 10.1038/bjc.2011.475 }}</ref>的研究都表明被动吸菸者患肺癌风险在显著增加<ref name="Taylor">{{cite journal | vauthors = Taylor R, Najafi F, Dobson A | title = Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent | journal = International Journal of Epidemiology | volume = 36 | issue = 5 | pages = 1048–59 | date = October 2007 | pmid = 17690135 | doi = 10.1093/ije/dym158 | url = http://ije.oxfordjournals.org/content/36/5/1048.long | archive-url = https://web.archive.org/web/20110805173006/http://ije.oxfordjournals.org/content/36/5/1048.long | deadurl = no | archive-date = 2011年8月5日 }}</ref>。和吸菸者共同生活的人患病风险增加20-30%，而工作环境中有二手菸的人其患病风险增加16-19%<ref>{{cite web|title=Frequently asked questions about second hand smoke|url=http://www.who.int/tobacco/research/secondhand_smoke/faq/en/index.html|work=World Health Organization|access-date=2012年7月25日|deadurl=no|archive-url=https://web.archive.org/web/20130101163934/http://www.who.int/tobacco/research/secondhand_smoke/faq/en/index.html|archive-date=2013年1月1日}}</ref>。而研究亦顯示{{tsl|en|sidestream smoke|側流菸|}}比直接吸菸更危险<ref name="Schick" />。美国每年有大约3,400人死于被动吸菸造成的肺癌<ref name="Alberg" />。

大麻和菸草菸雾中含有许多相同致癌物<ref>{{cite journal | vauthors = Greydanus DE, Hawver EK, Greydanus MM, Merrick J | title = Marijuana: current concepts(†) | journal = Frontiers in Public Health | volume = 1 | issue = 42 | pages = 42 | date = October 2013 | pmid = 24350211 | pmc = 3859982 | doi = 10.3389/fpubh.2013.00042 }}</ref>，但抽[[大麻属|大麻]]对患肺癌风险的影响还不清楚<ref>{{cite journal | vauthors = Owen KP, Sutter ME, Albertson TE | title = Marijuana: respiratory tract effects | journal = Clinical Reviews in Allergy & Immunology | volume = 46 | issue = 1 | pages = 65–81 | date = February 2014 | pmid = 23715638 | doi = 10.1007/s12016-013-8374-y }}</ref><ref>{{cite journal | vauthors = Joshi M, Joshi A, Bartter T | title = Marijuana and lung diseases | journal = Current Opinion in Pulmonary Medicine | volume = 20 | issue = 2 | pages = 173–9 | date = March 2014 | pmid = 24384575 | doi = 10.1097/mcp.0000000000000026 }}</ref>。2013年的一篇回顾性文章并未发现轻度到中度吸食大麻会使患肺癌风险增加<ref>{{cite journal | vauthors = Tashkin DP | title = Effects of marijuana smoking on the lung | journal = Annals of the American Thoracic Society | volume = 10 | issue = 3 | pages = 239–47 | date = June 2013 | pmid = 23802821 | doi = 10.1513/annalsats.201212-127fr }}</ref>。而2014年的回顧性文章则发现吸食大麻会使肺癌风险增加一倍<ref>{{cite journal | vauthors = Underner M, Urban T, Perriot J, de Chazeron I, Meurice JC | title = [Cannabis smoking and lung cancer] | journal = Revue Des Maladies Respiratoires | volume = 31 | issue = 6 | pages = 488–98 | date = June 2014 | pmid = 25012035 | doi = 10.1016/j.rmr.2013.12.002 }}</ref>。

===氡氣===
[[氡|氡]]是一种无色无味的[[气体|气体]]，由[[地球地壳|地壳]]中存在的[[铀|铀]]的衰变产物[[镭|镭]]裂變後生成。这些放射衰变产物会使遗传物质电离，進而導致基因產生某些致癌突变。氡气是美国肺癌的第二常见的暴露因子<ref>{{cite journal | vauthors = Choi H, Mazzone P | title = Radon and lung cancer: assessing and mitigating the risk | journal = Cleveland Clinic Journal of Medicine | volume = 81 | issue = 9 | pages = 567–75 | date = September 2014 | pmid = 25183848 | doi = 10.3949/ccjm.81a.14046 | url = http://www.ccjm.org/content/81/9/567.long }}</ref>。每年导致约21,000人死亡<ref>{{cite web | title=Radon (Rn) Health Risks | publisher=EPA | url=http://www.epa.gov/radon/healthrisks.html | deadurl=no | archiveurl=https://web.archive.org/web/20081020231845/http://www.epa.gov/radon/healthrisks.html | archivedate=2008-10-20 }}</ref>。氡气浓度每立方米升高100[[貝可萊爾|贝可]]（100 Bq/m³），其致癌风险就会增加8-16%<ref>{{cite journal |vauthors=Schmid K, Kuwert T, Drexler H | title=Radon in Indoor Spaces: An Underestimated Risk Factor for Lung Cancer in Environmental Medicine | journal=Dtsch Arztebl Int | volume=107 | issue=11 | pages=181–6 | date=March 2010 | pmid=20386676 | pmc=2853156 | doi=10.3238/arztebl.2010.0181 | url= }}</ref>。 氡气含量随区域和下层土壤、岩石的成分变化而不同。美国每15个家庭中就有大约一个的氡气水平超过了建议量每升4皮居里（4 [[居里_(单位)|pCi]]/l）<ref name="EPA radon" />。「密閉」、「通風不足」、「一樓的地板有裂縫，使得土壤中的氡逸散到室內」的建築，將有較高濃度的[[氡|氡]]。

===石棉===
[[石棉|石棉]]可导致多种肺病，包括肺癌。石棉者和吸菸會產生[[协同作用|協同作用]]，大幅增加罹患肺癌的機會<ref name="O'Reilly" />。吸菸者工作环境中有石棉时，其患肺癌风险較一般人高了45倍<ref>{{cite book | vauthors = Tobias J, Hochhauser D | title=Cancer and its Management | publisher=Wiley-Blackwell | year=2010 | page=199 | chapter=Chapter 12 | edition=6th | isbn=978-1-4051-7015-4 }}</ref>。石棉也可导致[[胸膜|胸膜]]癌變，稱為[[間皮瘤|間皮瘤]]（和肺癌不同）<ref>{{cite book | vauthors = Davies RJ, Lee YC | title=Oxford Textbook Medicine | publisher=OUP Oxford | year=2010 | chapter=18.19.3 | edition=5th | isbn=978-0-19-920485-4 }}</ref>。

===空氣汙染物===
戶外空氣汙染物會增加罹患肺癌的風險，特別是燃燒化石燃料產生的廢氣<ref name="MurrayNadel52"/>。懸浮细[[懸浮粒子|颗粒]]（PM<sub>2.5</sub>）和{{link-en|硫酸盐气溶胶|Stratospheric sulfur aerosols}}也會稍微提升风险，此類汙染物常來自於汽車排放的廢氣<ref name="MurrayNadel52" /><ref>{{cite journal | vauthors = Chen H, Goldberg MS, Villeneuve PJ | title = A systematic review of the relation between long-term exposure to ambient air pollution and chronic diseases | journal = Reviews on Environmental Health | volume = 23 | issue = 4 | pages = 243–97 | date = Oct–Dec 2008 | pmid = 19235364 | doi = 10.1515/reveh.2008.23.4.243 }}</ref>。[[二氧化氮|二氧化氮]]浓度每增加10 [[ppb|ppb]]，人患肺癌风险就上升14%<ref>{{cite journal | vauthors = Clapp RW, Jacobs MM, Loechler EL | title = Environmental and occupational causes of cancer: new evidence 2005-2007 | journal = Reviews on Environmental Health | volume = 23 | issue = 1 | pages = 1–37 | date = Jan–Mar 2008 | pmid = 18557596 | pmc = 2791455 | doi = 10.1515/REVEH.2008.23.1.1 }}</ref>。据估計，1-2%的肺癌由户外空气污染所致<ref name="MurrayNadel52" />。

初步证据支持[[室內空氣污染|室内空气污染]]会使患肺癌风险增加，包括做饭和取暖时燃烧木材、木炭、粪便或作物残茬<ref name="Lim2012">{{cite journal|title=Biomass fuels and lung cancer|date=January 2012|journal=Respirology|issue=1|doi=10.1111/j.1440-1843.2011.02088.x|volume=17|pages=20–31|pmid=22008241|vauthors=Lim WY, Seow A}}</ref>。暴露于室内煤烟的女性，罹患肺癌风险會提升大概一倍，许多[[生物质|生物质]]燃烧后的副产品是已知或可疑的致癌物<ref name="Sood2012"/>。这一风险影響全球大约24亿人<ref name="Lim2012" />，據信約有1.5%的肺癌死亡病例是由此导致<ref name="Sood2012">{{cite journal|last=Sood|first=A|title=Indoor fuel exposure and the lung in both developing and developed countries: an update.|journal=Clinics in chest medicine|volume=33|issue=4|pages=649–65|pmid=23153607|doi=10.1016/j.ccm.2012.08.003|date=2012年12月}}</ref>。

===遺傳因素===
约8%肺癌由遗传因素所致<ref>{{cite journal | vauthors = Yang IA, Holloway JW, Fong KM | title = Genetic susceptibility to lung cancer and co-morbidities | journal = Journal of Thoracic Disease | volume = 5 Suppl 5 | issue = Suppl. 5 | pages = S454–62 | date = October 2013 | pmid = 24163739 | pmc = 3804872 | doi = 10.3978/j.issn.2072-1439.2013.08.06 }}</ref>。若亲属中有肺癌患者时患病风险會增加一倍， 本疾病可能由{{tsl|en|polygenic disorder|多基因性疾病|多基因}}共同調控<ref>{{Cite book | vauthors = Dela Cruz CS, Tanoue LT, Matthay RA | title=Fishman's Pulmonary Diseases and Disorders | publisher=McGraw-Hill | veditors = Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM | year=2015 | chapter=Chapter 109: Epidemiology of lung cancer | page=1673 | edition=5th | isbn=978-0-07-179672-9 }}</ref>。目前已知5、6和15号染色体上的基因[[單核苷酸多態性|多态性]]会影响患肺癌的风险<ref>{{cite journal | vauthors = Larsen JE, Minna JD | title = Molecular biology of lung cancer: clinical implications | journal = Clinics in Chest Medicine | volume = 32 | issue = 4 | pages = 703–40 | date = December 2011 | pmid = 22054881 | pmc = 3367865 | doi = 10.1016/j.ccm.2011.08.003 }}</ref>。

===其他原因===
许多其它物质、职业及所处环境都与肺癌有关联。[[国际癌症研究机构|国际癌症研究机构]]（IARC）声称有“充足证据证明”以下物质是肺部的致癌物<ref name='WHOListLungCancer'>{{cite journal | vauthors = Cogliano VJ, Baan R, Straif K, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Wild CP | display-authors = 6 | title = Preventable exposures associated with human cancers | journal = Journal of the National Cancer Institute | volume = 103 | issue = 24 | pages = 1827–39 | date = December 2011 | pmid = 22158127 | pmc = 3243677 | doi = 10.1093/jnci/djr483 | url = http://monographs.iarc.fr/ENG/Classification/Table4.pdf | archive-url = https://web.archive.org/web/20120920150724/http://monographs.iarc.fr/ENG/Classification/Table4.pdf | deadurl = no | archive-date = 2012年9月20日 }}</ref>：
*某些金属（[[铝|铝]]制品、[[镉|镉]]及其化合物、[[铬|铬]](VI)化合物、[[铍|铍]]及其化合物、[[钢铁|钢铁]]、[[镍|镍]]化合物、[[砷|砷]]及无机砷化合物、地下[[赤铁矿|赤铁矿]]）
*一些燃烧产物（不完全燃烧产物、[[煤|煤]]（家庭烧煤所致室内排放物）、煤的气化物、煤-[[焦油|焦油]]沥青、[[焦炭|焦炭]]生产所排放物质、煤烟、[[柴油引擎|柴油机]]排放气体）
* 电离辐射（[[X射线|X射线]]、[[伽马射线|伽马射线]]、[[钚|钚]]）
* 一些有害气体（[[甲醚|甲醚]]（工业级）、双氯甲醚（氯甲基）、硫[[芥子毒气|芥]]、{{link-en|长春新碱-强的松-氮芥-甲基苄肼混合物|Mustargen Oncovin Procarbazine Prednisone|MOPP}}、油画释放的气体）
* [[橡胶|橡胶]]制品和结晶[[二氧化硅|矽尘]]
* {{tsl|en|systemic sclerosis|硬皮症}}患者罹患肺癌風險稍高。

==致病機轉==
{{See also|癌变}}
和许多其它癌症类似，肺癌也始于原[[癌基因|癌基因]]的激活或[[抑癌基因|抑癌基因]]的灭活<ref>{{cite journal | vauthors = Cooper WA, Lam DC, O'Toole SA, Minna JD | title = Molecular biology of lung cancer | journal = Journal of Thoracic Disease | volume = 5 Suppl 5 | issue = Suppl. 5 | pages = S479-90 | date = October 2013 | pmid = 24163741 | pmc = 3804875 | doi = 10.3978/j.issn.2072-1439.2013.08.03 | archive-url = https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804875/pdf/jtd-05-S5-S479.pdf | deadurl = no | archive-date = 2017年9月10日 }}</ref>。而致癌物正是誘發這些變的因素<ref>{{Cite book | vauthors = Tobias J, Hochhauser D | title=Cancer and its Management | publisher=Wiley-Blackwell | year=2010 | page=200 | chapter=Chapter 12 | edition=6th | isbn=978-1-4051-7015-4 }}</ref>。''{{tsl|en|Ras (protein)||K-ras}}''原癌基因的[[突变|突变]]导致10-30%的肺腺癌<ref name="NEJM-molecular" /><ref name="Aviel-Ronen" />。大概4%的非小细胞肺癌与一个{{tsl|en|EML4-ALK}}[[酪氨酸激酶|酪氨酸激酶]]融合基因有关<ref>{{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=212 | chapter=Chapter 5 | isbn=978-1-4377-1781-5 }}</ref>。[[表观遗传学|表观遗传学]]的变化——如[[DNA甲基化|DNA甲基化]]，[[组织蛋白|组织蛋白]]尾部修饰或小核糖核酸（[[微RNA|微RNA]]）调控的改变可能会导致抑癌基因的灭活<ref name="Jakopovic">{{Cite journal|title=Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793201/pdf/fonc-03-00261.pdf|last=Jakopovic|first=M|date=2013年10月|journal=Frontiers in Oncology|issue=261|doi=10.3389/fonc.2013.00261|volume=3|pmc=3793201|pmid=24130964|author3=Balasubramaniam S|author2=Thomas A}}</ref>。

[[表皮生长因子受体|表皮细胞生长因子受体]]（EGFR）调控细胞增殖、[[细胞凋亡|凋亡]]、[[血管新生|血管生成]]和肿瘤侵袭<ref name="NEJM-molecular" />。EGFR基因的突變和增幅是非小細胞癌常見的致病機轉，因此EGFR抑制劑可以用於某些肺癌的治療<ref name="NEJM-molecular" />。其它经常发生突变或扩增的基因有{{tsl|en|c-MET}}、{{tsl|en|NKX2-1}}、{{tsl|en|LKB1}}、{{tsl|en|PIK3CA}}和{{tsl|en|BRAF}}<ref name="NEJM-molecular" />。

其细胞株系起源機制尚不完全清楚<ref name="Harrison" />。机理可能涉及[[干细胞|干细胞]]的异常活化。在气道近端，表达{{link-en|角蛋白5|keratin 5}}的干细胞最易發生癌變，导致肺鳞状细胞癌。在气道中段，{{tsl|en|club cell|支氣管無纖毛分泌細胞|}}（club cell）和[[神经上皮細胞|神经上皮細胞]]等會表達{{tsl|en|uteroglobin|子宮球蛋白|}}的細胞具幹細胞性質。小细胞肺癌可能来源于这些细胞系<ref name="Mulvihill">{{cite journal|title=The role of stem cells in airway repair: implications for the origins of lung cancer|date=February 2013|journal=Chinese Journal of Cancer|issue=2|doi=10.5732/cjc.012.10097|volume=32|pages=71–4|pmc=3845611|pmid=23114089|vauthors=Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B}}</ref>，或[[神经分泌细胞|神经分泌细胞]]<ref name="Harrison" />，也可能会表达[[CD44|CD44]]<ref name="Mulvihill" />。

肺癌細胞在原發時大多為上皮细胞型，但該型細胞並不利遠端轉移，必須要轉變為[[间充质|间质]]细胞型才可以進行遠端轉移，該現象稱為{{le|上皮間質轉化|Mesenchymal–epithelial transition}}。涉及轉化的蛋白包含[[蛋白激酶B|Akt]]/{{link-en|GSK3B|GSK3B|GSK3Beta}}、{{tsl|en|MEK-ERK}}、{{link-en|Fas受体|Fas receptor|Fas}}和Par6等<ref name="Powell_2013">{{cite journal | vauthors = Powell CA, Halmos B, Nana-Sinkam SP | title = Update in lung cancer and mesothelioma 2012 | journal = American Journal of Respiratory and Critical Care Medicine | volume = 188 | issue = 2 | pages = 157–66 | date = July 2013 | pmid = 23855692 | pmc = 3778761 | doi = 10.1164/rccm.201304-0716UP | archive-url = https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3778761/pdf/rccm.201304-0716UP.pdf | deadurl = no | archive-date = 2017年9月10日 }}</ref>。

[[COPD|COPD]]和[[肺纤维化|肺纤维化]]（{{link-en|α1-抗胰蛋白酶|α1-antitrypsin}}缺乏）可能增加肺癌易感性；此外，吸烟者补充[[β-胡萝卜素|β-胡萝卜素]]也会增加患肺癌的危险性。空气污染和雪茄烟雾中含有致癌物质，这些致癌物质可能存在一定的致癌风险，但尚未显示可引起肺癌。患者若有其他的肺部疾病（如[[肺结核|肺结核]]）所致瘢痕，那么他们的患癌风险也将增加。<ref name="Merck"/>

[[呼吸道上皮细胞|呼吸道上皮细胞]]需长时间暴露于促癌物质下并逐渐积累多种基因突变才能成为[[新生物|腫瘤]]。刺激细胞生长（K-ras, MYC）的[[基因|基因]]突变逐渐导致生长因子受体（EGFR，HER2/neu）信号异常，抑制凋亡（BCL-2），引起异常细胞增殖。此外，肿瘤抑制基因的突变（p53、APC）亦可导致癌症。<ref name="Merck"/>

==诊断==
[[Image:Thorax_CT_peripheres_Brronchialcarcinom_li_OF.jpg|thumb]]扫描显示左肺一癌性肿瘤]]
當病人的症狀疑為肺癌時，{{tsl|en|chest radiograph|胸部影像學|胸部影像學}}檢查可提供初步的檢查和評估。肺癌在影像學的表現包括如单个肿块、多发肿块、孤立的肺结节等等。另外還有肺门增大、[[縱膈|纵隔]]增宽（可能代表縱膈腔[[淋巴結|淋巴結]]轉移）、{{tsl|en|atelectasis|肺不张|}}、气管支气管狭窄、肺實變，未緩解的的实质浸润、空洞。或其他原因無法解釋的{{tsl|en|pleural effusion|肋膜積水|}}<ref name="Merck" /><!--此段摘自中文原版的默克诊疗手册，直接译自英文不及中文原版准确-->。[[X射线计算机断层成像|電腦斷層]]（CT）可以提供更多相關資訊，例如說腫瘤的擴散程度及類別，也相較胸部X光片更能發現縱膈腔後的腫瘤。但上述影像學檢查僅能夠提供診斷上的參考，確診必須透過{{link-en|细胞病理学|Cytopathology}}證實。因此可以透過{{link-en|支气管镜|Bronchoscopy}}或CT引导下的组织活检，進行{{link-en|组织病理学|Histopathology}}检查的取样<ref name="Collins" />。

胸片上肺癌通常表现为一个{{link-en|單一肺結節|solitary pulmonary nodule}}。但由於有許多症狀類似的疾病，因此仍須配合其他檢查以進行[[鉴别诊断|鉴别诊断]]。與肺癌在影像學類似的疾病包含其他腫瘤的轉移、{{link-en|错构瘤|hamartomas}}、感染肉芽腫（如肺[[结核|结核]]、{{tsl|en|histoplasmosis|組織孢漿菌症|}}、{{tsl|en|coccidioidomycosis|球黴菌症|}}等等）<ref>{{cite book|title=Fishman's Pulmonary Diseases and Disorders|publisher=McGraw-Hill|year=2015|isbn=978-0-07-179672-9|edition=5th|page=1685|chapter=Chapter 110: Approach to the patient with pulmonary nodules|vauthors=Ost D|veditors=Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM}}</ref>，其他导致单个肺结节但不太常见的原因包括{{link-en|支气管源性囊肿|bronchogenic cysts}}、[[腺瘤|腺瘤]]、[[动静脉畸形|动静脉畸形]]、{{link-en|肺隔离症|pulmonary sequestration}}、{{link-en|类风湿结节|rheumatoid nodules}}、{{link-en|肉芽肿|Granuloma}}病伴多血管炎或[[淋巴瘤|淋巴瘤]]<ref>{{Cite book|title=Fishman's Pulmonary Diseases and Disorders|last=Miller|first=WT|publisher=McGraw-Hill|year=2008|isbn=0-07-145739-9|edition=4th|page=486}}</ref>。肺癌亦可能在進行其他无关原因做胸部X片或CT扫描时{{tsl|en|incidentaloma|偶見瘤|意外發現}}<ref>{{cite journal|title=Chest CT incidentalomas: thyroid lesions, enlarged mediastinal lymph nodes, and lung nodules|date=March 2012|journal=Cancer Imaging|issue=1|doi=10.1102/1470-7330.2012.0006|volume=12|pages=41–8|pmc=3335330|pmid=22391408|vauthors=Frank L, Quint LE}}</ref>。肺癌需要通过对可疑组织的临床和影像学特征进行[[组织学|组织学]]检查方能确诊<ref name="Harrison" /><ref name="Holland-Frei78" />。[[临床实践指南|临床实践指南]]推荐了肺{{tsl|en|Nodule (medicine)|結節 (醫學)|結節}}的监测频率<ref name="ACCPandATSfive">{{cite web|url=http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/|title=Five Things Physicians and Patients Should Question|date=September 2013|work={{tsl|en|Choosing Wisely||Choosing Wisely}}: an initiative of the {{tsl|en|ABIM Foundation||ABIM Foundation}}|publisher=American College of Chest Physicians and American Thoracic Society|author1=American College of Chest Physicians|author2=American Thoracic Society|page=|access-date=2013年1月6日|deadurl=no|archive-url=https://web.archive.org/web/20131103063427/http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/|archive-date=2013年11月3日}}</ref>。CT扫描不应使用过长时间或过于频繁，因为会增加人们接触到的射线量<ref name="ACCPandATSfive" />。

{{Le|毛玻璃樣斑塊|Ground-glass opacity}}（Ground-glass opacity，GGO）是描述胸部照影中的肺部毛玻璃樣病灶，過去大多被視為良性變化。但在更進一步的解剖研究後，發現有些GGO具有惡性潛勢。良性的GGO包含局部間質纖維化（focal interstitial fibrosis）、發炎，或是出血。惡性的狀況則包含{{Le|異形腺瘤性增生|Atypical adenomatous hyperplasia}}（AAH）、{{Le|原位肺腺癌|Adenocarcinoma in situ of the lung}}（AIS），或{{Le|微侵犯型肺腺癌|Minimally invasive adenocarcinoma of the lung}}（MIA），以及鱗屑樣為主型肺腺癌（lepidic-predominant invasive adenocarcinomas，LPA）等<ref>{{Cite journal|title=Pulmonary ground-glass opacity: computed tomography features, histopathology and molecular pathology|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344841/|last=Gao|first=Jian-Wei|last2=Rizzo|first2=Stefania|date=2017-2|journal=Translational Lung Cancer Research|issue=1|doi=10.21037/tlcr.2017.01.02|others=|year=|volume=6|page=|pages=68–75|issn=2218-6751|pmc=5344841|pmid=28331826|last3=Ma|first3=Li-Hong|last4=Qiu|first4=Xiang-Yu|last5=Warth|first5=Arne|last6=Seki|first6=Nobuhiko|last7=Hasegawa|first7=Mizue|last8=Zou|first8=Jia-Wei|last9=Li|first9=Qian}}</ref>。由於GGO的惡性機率高達63%，因此在癌早期發現的角色也越顯重要<ref>{{Cite journal|title=Ground glass opacities management in the lung cancer screening era|author=|url=http://atm.amegroups.com/article/view/16332|last=Migliore|first=Marcello|last2=Fornito|first2=Mariaconcetta|date=2017-08-31|journal=Annals of Translational Medicine|issue=5|doi=10.21037/16332|others=|year=|volume=6|page=|language=|issn=2305-5847|pmid=|last3=Palazzolo|first3=Manuela|last4=Criscione|first4=Alessandra|last5=Gangemi|first5=Mariapia|last6=Borrata|first6=Francesco|last7=Vigneri|first7=Paolo|last8=Nardini|first8=Marco|last9=Dunning|first9=Joel}}</ref>。

===分类===
[[File:Pie_chart_of_lung_cancers_-_zh.png|thumb]]。參考文獻：[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044470/table/T2/ Table 2] {{webarchive|url=https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044470/table/T2/ |date=2017-09-10 }} in: {{cite journal | vauthors = Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA | title = Comparison of aspects of smoking among the four histological types of lung cancer | journal = Tobacco Control | volume = 17 | issue = 3 | pages = 198–204 | date = June 2008 | pmid = 18390646 | pmc = 3044470 | doi = 10.1136/tc.2007.022582 }}</ref>。]]
{| class="wikitable floatright" style="text-align:center;font-size:90%;width:25%;margin-left:1em"
|+ style="background:#E5AFAA;"|'''按组织类型和年龄调整的肺癌[[发病率|发生率]]'''<ref name="MurrayNadel52" />
|- style="background: #E5AFAA;text-align:center;font-size:90%;"
! abbr="Type" | 组织类型
! abbr="Frequency" | 每年每100,00人的发病率
|-
| 所有类型
| 66.9
|-
| 腺癌
| 22.1
|-
| 鳞狀上皮癌
| 14.4
|-
| 小细胞癌
| 9.8
|}

肺癌的分類須透過{{tsl|en|histopathology|組織病理學|組織病理分型}}<ref name="Holland-Frei78" />，分類對於治療策略的選擇跟預測療效相當重要。肺癌屬於[[癌|上皮癌]]，意即腫瘤發源自[[上皮組織|上皮細胞]]，可根據[[显微镜|顯微鏡]]下觀察到的癌細胞的大小和形態對肺癌進行分類。為方便治療，肺癌可大致分為{{tsl|en|non-small-cell lung carcinoma|非小細胞肺癌|非小細胞癌}}和[[小细胞肺癌|小細胞肺癌]]<ref name="Robbins" />。

====非小細胞癌====
[[Image:Squamous_carcinoma_lung_2_cytology.jpg|thumb]]下的{{tsl|en|squamous-cell carcinoma|鱗狀上皮癌}}，{{tsl|en|FNA specimen|細針抽吸樣本}}（FNA），{{tsl|en|Pap stain|柏氏染色}}]]

非小細胞癌（NSCLC）可粗分為三大類：[[肺腺癌|肺腺癌]]、{{tsl|en|squamous-cell lung carcinoma|肺鱗狀上皮癌|鱗狀上皮癌}}，和{{tsl|en|large-cell lung carcinoma|大細胞肺癌|大細胞癌}}<ref name="Harrison" />。

接近40%的肺癌屬於肺腺癌，腺癌一般起源於周圍肺組織<ref name="Holland-Frei78"/>。雖然多數腺癌與吸菸有關，但在從未吸菸者、一生抽菸少於100根，以及曾中度吸菸並已戒治者的肺癌患者中，肺腺癌亦為最常見類型<ref name="Harrison" /><ref name="Subramanian">{{cite journal | vauthors = Subramanian J, Govindan R | title = Lung cancer in never smokers: a review | journal = Journal of Clinical Oncology | volume = 25 | issue = 5 | pages = 561–70 | date = February 2007 | pmid = 17290066 | doi = 10.1200/JCO.2006.06.8015 | publisher = American Society of Clinical Oncology }}</ref>。而肺癌的其中一種亞型{{tsl|en|bronchioloalveolar carcinoma|細支氣管肺泡癌|}}，則多見於女性未吸菸者，其長期存活率較佳<ref name="Raz"/>。

鱗癌大概占肺癌的30%，一般位於大氣道附近。癌組織中央常可發現因細胞[[壞死|壞死]]而形成的空腔<ref name="Holland-Frei78" />。大約9%的肺癌為大細胞癌。之所以稱其為大細胞癌是因為癌細胞體積大，[[細胞質|細胞質]]過量，[[細胞核|細胞核]]大，[[核仁|核仁]]明顯<ref name="Holland-Frei78" />。

====小细胞肺癌====
[[Image:Lung_small_cell_carcinoma_(1)_by_core_needle_biopsy.jpg|thumb]]
[[小细胞肺癌|小细胞肺癌]]（SCLC）的癌细胞内含有緻密的神经内分泌颗粒（即含有[[神经分泌细胞|神经]]内分泌[[激素|激素]]的[[囊泡|囊泡]]），因此這類肿瘤可能會有内分泌相關的副癌综合征<ref name="Rosti" />。多数小细胞肺癌发生在大的气道（主支气管和次级[[支氣管|支气管]]）<ref name="Collins" />。病程中癌组织生长迅速，发生扩散早，60-70%的患者就诊时已有廣泛侵犯的情形（意即一次放射線治療無法打完）。小细胞癌和吸烟有着极大的关系<ref name="Harrison" />。

====其他====
公认的主要组织学亚型有四种，有些癌组织可能同時擁有不同亚型<ref name=Robbins>{{cite book | vauthors = Kumar V, Abbas AK, Aster JC | year=2013 | title=Robbins Basic Pathology |edition=9th | publisher=Elsevier Saunders | page=505 | chapter=12 | isbn=978-1-4377-1781-5 }}</ref>，如腺鱗癌<ref name="Holland-Frei78" />。罕见的亚型包括：[[腺瘤|腺瘤]]、{{tsl|en|lung carcinoid|肺類癌|類癌}}和肉瘤樣癌（sarcomatoid carcinomas）<ref name="Holland-Frei78" />。

===转移===
{| class="wikitable floatright" style="text-align:center;font-size:90%;width:25%;margin-left:1em"
|+ style="background:#E5AFAA;"|'''原發性肺癌的{{tsl|en|Napsin-A|Napsin-A}}及{{tsl|en|TTF-1|TTF-1}}{{tsl|en|immunostaining|免疫染色}}'''<ref name="Harrison" />
|- style="background: #E5AFAA;text-align:center;font-size:90%;"
! abbr="Type" | 免疫分型
! abbr="Nap=A" | Napsin-A
! TTF-1
!P40
|-
| 鳞狀上皮癌
| 阴性
| 阴性
|阳性
|-
| 腺癌
| 阳性
| 阳性
|阴性
|-
| 小細胞癌
| 阴性
| 阳性
|阴性
|}

肺部為身體其他腫瘤常見的轉移位置。继发性肿瘤可根据其原发部位分类，如扩散到肺部的乳腺癌被称为转移性乳腺癌。转移性肿瘤在胸片中常显示为典型的圆形<ref name="Seo" />。

而原发性肺癌本身最常见的转移部位是脑、骨、肝脏和[[肾上腺|肾上腺]]<ref name="Holland-Frei78" />。对活检组织进行{{tsl|en|Immunostaining|免疫染色}}通常有助于确定癌症原发部位<ref name="pmid18784820">{{cite journal |vauthors=Tan D, Zander DS |title=Immunohistochemistry for Assessment of Pulmonary and Pleural Neoplasms: A Review and Update |journal=Int J Clin Exp Pathol |volume=1 |issue=1 |pages=19–31 |year=2008|pmid=18784820 |pmc=2480532 }}</ref>。若腫瘤細胞出現{{tsl|en|Napsin-A|Napsin-A}}、{{tsl|en|TTF-1|TTF-1}}、CK7和CK20等標記，可以協助確認腫瘤的亞型。如SCLC是源自於神經內分泌細胞，因此可能會表現[[神經元黏附分子|CD56]]、[[神經元黏附分子|神經元黏附分子]]、{{tsl|en|synaptophysin|突觸素}}，或{{tsl|en|chromogranin|嗜鉻粒蛋白}}等等<ref name="Harrison" />。

===分期===
{{see also|肺癌分期}}

[[癌症分期|癌症分期]]是对其从原发部位扩散的程度进行评价<ref name="Holland-Frei2">{{cite book | vauthors=Connolly JL, Goldsmith JD, Wang HH, etal | title=Holland-Frei Cancer Medicine | edition=8th | chapter=37: Principles of Cancer Pathology | publisher=People's Medical Publishing House | year=2010 |isbn=978-1-60795-014-1 }}</ref>，是影响肺癌[[预后|预后]]和潜在治疗措施的因素之一<ref name="Harrison" /><ref name="Holland-Frei2" />。最初对非小细胞肺癌的分期评估使用的是{{link-en|TNM分期法|TNM staging system}}。是基于原发肿瘤（'''T'''umor）的大小，是否累及淋巴结（lymph '''N'''ode）及有否远处转移（'''M'''etastasis）<ref name="Harrison" />。

{| class="wikitable" style="text-align:center;font-size:90%;margin-left:1em;background:#E5AFAA;"
|+ 肺癌的TNM分期法（AJCC第八版）<ref name="AJCC8">{{Cite journal|title=The Eighth Edition Lung Cancer Stage Classification|author=|url=http://journal.chestnet.org/article/S0012-3692(16)60780-8/fulltext|last=Detterbeck|first=Frank C.|last2=Boffa|first2=Daniel J.|date=2017-01-01|journal=Chest|issue=1|doi=10.1016/j.chest.2016.10.010|others=|year=|volume=151|page=|pages=193–203|language=|issn=0012-3692|pmid=|last3=Kim|first3=Anthony W.|last4=Tanoue|first4=Lynn T.}}</ref>
|-
|
{| class="wikitable"
|-
! colspan="3" | T：原发性肿瘤
|-
| rowspan="2" | TX
| rowspan="2" | 任何的：
|無法評估
|-
| 肿瘤细胞存在于痰或支气管洗出液中，但在成像或支气管镜检查中没有发现肿瘤
|-
| T0
| colspan="2" | 无原发肿瘤依据
|-
| Tis
| colspan="2" | [[原位癌|原位癌]]
|-
| T1
| colspan="2" | 腫瘤小於三公分，且腫瘤未侵犯至其他週邊組織、臟層胸膜。
|-
| rowspan="3" | T1a
| colspan="2" | 腫瘤不大於1公分（ ≤１ cm）
|-
| colspan="2" |位於中心氣道表面的腫瘤。大小不限，只要三公分以下都歸於此類，但腫瘤僅限於氣管及支氣管壁。
|-
| colspan="2" |微侵犯的腺癌
|-
| T1b
| colspan="2" |腫瘤大於1公分（ >1 cm），但不大於2公分（ ≤2 cm）
|-
|T1c
| colspan="2" |腫瘤大於2公分（ >2 cm），但不大於3公分（ ≤3 cm）
|-
| rowspan="3" | T2
| rowspan="3" |任何的：
|腫瘤大於3公分（ >3 cm），但不大於5公分（ ≤5 cm）
|-
| 腫瘤進犯臟層[[胸膜|胸膜]]
|-
| 因腫瘤引起肺塌陷或阻塞性肺炎，影像上延伸至肺門。
|-
| T2a
| colspan="2" |腫瘤大於3公分（ >3 cm），但不大於4公分（ ≤4 cm）
|-
| T2b
| colspan="2" |腫瘤大於4公分（ >4 cm），但不大於5公分（ ≤5 cm）
|-
| rowspan="3" | T3
| rowspan="3" |任何的：
|腫瘤大於5公分（ >5 cm），但不大於7公分（ ≤5 cm）
|-
|腫瘤進犯胸壁、[[心包|心包]]、膈神經
|-
|單一肺葉有超過一顆獨立結節
|-
| rowspan="2" | T4
| rowspan="2" |任何的：
|腫瘤侵犯至[[/|縱隔腔]]、[[橫膈|橫膈]]、心臟、大血管、[[喉返神經|喉返神經]]、氣管隆凸（Carina）、[[氣管|氣管]]、食道、[[脊髓損傷|脊椎骨]]
|-
|腫瘤細胞同時出現於同側不同肺葉
|}
| style="vertical-align:top;" |
{| class="wikitable"
|-
! colspan="2" | N：淋巴结
|-
| NX
| 区域淋巴结，且無法評估
|-
| N0
|無周邊淋巴結侵犯、轉移
|-
| N1
|[[腫瘤|腫瘤]]侵犯或轉移至原發腫瘤同側之支氣管周圍淋巴結、肺內淋巴結或肺門淋巴結。
|-
| N2
|腫瘤侵犯或轉移至原發腫瘤同側之縱隔腔淋巴結或氣管隆凸下淋巴結。
|-
| N3
| 腫瘤侵犯或轉移至原發腫瘤對側之縱隔腔或肺門淋巴結，或有無論同對側的鎖骨上淋巴結轉移。
|}
{| class="wikitable "  style="width: 100%"
|-
! colspan="3" | M：转移
|-
| MX
| colspan="2" | 無法評估
|-
| M0
| colspan="2" |無遠端轉移
|-
| rowspan="3" | M1a
| rowspan="3" | 任何的：
| 對側肺獨立結節
|-
| 肋膜獨立結節
|-
| 有惡性腫瘤引致的肋膜積液、心包積液
|-
| M1b
| colspan="2" | 單一胸外轉移
|-
|M1c
| colspan="2" |多重胸外轉移
|}
|}

使用TNM分期系统可将非小細胞肺癌分为隐匿癌、0、IA、IB、IIA、IIB、IIIA、IIIB、IIIC、IVA，和IVB期。这一分期系统可辅助选择治疗措施和评估预后<ref name="Rami-Porta">{{cite journal | vauthors = Rami-Porta R, Crowley JJ, Goldstraw P | title = The revised TNM staging system for lung cancer | journal = Annals of Thoracic and Cardiovascular Surgery | volume = 15 | issue = 1 | pages = 4–9 | date = February 2009 | pmid = 19262443 | url = http://www.atcs.jp/pdf/2009_15_1/4.pdf | archive-url = https://web.archive.org/web/20120509223416/http://www.atcs.jp/pdf/2009_15_1/4.pdf | deadurl = no | archive-date = 2012年5月9日 }}</ref>。

小细胞肺癌被归入局限期（limited stage，只限于單側胸腔的一半，且能被纳入单一[[放射治疗|放射治疗]]區域）和广泛期（播散范围更广）<ref name="Harrison" />。但使用TNM系统进行分类有助于评估其预后<ref name="Rami-Porta" />。

对非小细胞肺癌和小细胞肺癌来说有两种分期评估方法：临床分期和外科手术分期。临床分期在根除性手術之前进行，主要以影像学检查结果（如[[X射线计算机断层成像|CT扫描]]和[[正电子发射计算机断层扫描|PET扫描]]）和组织活检结果为基础。外科手术分期在术中或术后进行，综合考虑手术和临床的结果，包括对胸腔淋巴结的手术取样<ref name="Holland-Frei78" />。

{| class="wikitable floatleft" style="text-align:center;font-size:90%;margin-left:1em;background:#E5AFAA;"
|+ '''根據TNM分期法對肺癌患者的分期'''<ref name="AJCC8" />
|-
! TNM
!'''期組'''
|-
| T1 N0 M0
| IA
|-
| T2a N0 M0
| IB
|-
| T2b N0 M0
| IIA
|-
| T1-T2 N1 M0
| rowspan="2" | IIB
|-
| T3 N0 M0
|-
| T1–T2 N2 M0
| rowspan="3" | IIIA
|-
| T3 N1 M0
|-
| T4 N0–N1 M0
|-
| T1-T2 N3 M0
| rowspan="2" | IIIB
|-
| T3-T4 N2 M0
|-
|T3-T4 N3 M0
|IIIC
|-
| M1a-M1b
| IVA
|-
|M1c
|IVB
|}

<!--<gallery widths="200px" heights="200px" perrow="4" caption="图表：肺癌各分期主要特征">
File:Diagram showing stage 1A and 1B lung cancer CRUK 197.svg|肺癌IA和IB阶段
File:Diagram showing stage 2A lung cancer CRUK 213.svg|肺癌IIA阶段
File:Diagram showing one option for stage 2Ba lung cancer CRUK 176.svg|IIB阶段的肺癌
File:Diagram showing one option for stage 2Bb lung cancer CRUK 177.svg|其它肺癌IIB阶段的特征，T2b，但是如果肿瘤距离{{le|气管隆凸|Carina of trachea}}不到2 cm，为第三阶段
File:Diagram 1 of 3 showing stage 3A lung cancer CRUK 008.svg|肺癌IAA阶段
File:Diagram 2 of 3 showing stage 3A lung cancer CRUK 014.svg|如果出现图片两边任何一种症状，则处于肺癌IIIA阶段
File:Diagram 3 of 3 showing stage 3A lung cancer CRUK 017.svg|肺癌IIIA阶段
File:Diagram 1 of 2 showing stage 3B lung cancer CRUK 005.svg|肺癌IIIB阶段
File:Diagram 2 of 2 showing stage 3B lung cancer CRUK 011.svg|肺癌IIIB阶段
File:Diagram showing stage 4 lung cancer CRUK 232.svg|肺癌IV阶段
</gallery>  過時的圖表，須重繪-->

==预防==
[[File:cancerous_lung.jpg|thumb]]
避免吸菸和[[戒菸|戒菸]]是有效預防肺癌發生的方法<ref>{{cite journal | vauthors = Dela Cruz CS, Tanoue LT, Matthay RA | title = Lung cancer: epidemiology, etiology, and prevention | journal = Clinics in Chest Medicine | volume = 32 | issue = 4 | pages = 605–44 | date = December 2011 | pmid = 22054876 | pmc = 3864624 | doi = 10.1016/j.ccm.2011.09.001 | archive-url = https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864624/pdf/nihms468128.pdf | deadurl = no | archive-date = 2017年9月10日 }}</ref>。

===禁菸===
{{see also|禁菸}}
在大多数国家，大部分工业和家用的可致癌物质都已經鑑別出來，並明令規範，但吸菸仍相當普遍。限制吸烟是预防肺癌的首要目标，而戒菸是这个过程中最重要的一环<ref>{{cite journal | vauthors = Goodman GE | title=Lung cancer. 1: prevention of lung cancer | journal=Thorax | volume=57 | issue=11 | date=November 2002 | pages=994–999 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746232/pdf/v057p00994.pdf | pmid=12403886 | pmc=1746232 | doi=10.1136/thorax.57.11.994 | deadurl=no | archiveurl=https://web.archive.org/web/20170910181827/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746232/pdf/v057p00994.pdf | archivedate=2017-09-10 }}</ref>。

有更多西方国家通过政策干预来减少在餐馆和工作场所等公共区域的[[被动吸烟|被动吸烟]]<ref>{{cite journal | vauthors = McNabola A, Gill LW | title = The control of environmental tobacco smoke: a policy review | journal = International Journal of Environmental Research and Public Health | volume = 6 | issue = 2 | pages = 741–58 | date = February 2009 | pmid = 19440413 | pmc = 2672352 | doi = 10.3390/ijerph6020741 }}</ref>。[[不丹|不丹]]於2005年起已实行完全禁烟令<ref name="Bhutan" />，印度也从2008年10月开始也实行了公共场所禁烟令<ref>{{cite news | vauthors = Pandey G | title=Indian ban on smoking in public | url=http://news.bbc.co.uk/1/hi/world/south_asia/7645868.stm | publisher=[[英国广播公司|BBC]] | date=2008-10-02 | access-date=2012年4月25日 | deadurl=no | archive-url=https://web.archive.org/web/20090115143617/http://news.bbc.co.uk/1/hi/world/south_asia/7645868.stm | archive-date=2009年1月15日 }}</ref>。[[世界卫生组织|世界卫生组织]]（WHO）号召各国政府全面禁止菸草广告以防止年轻人沾染，WHO估计在实行这种禁令的国家烟草消费量已减少了至少16%<ref name="AUTOREF10">{{Cite press release |title=UN health agency calls for total ban on tobacco advertising to protect young |url=https://www.un.org/apps/news/story.asp?NewsID=26857 |publisher=[[联合国|United Nations]] News service |date=2008-05-30 |deadurl=no |archive-url=https://web.archive.org/web/20160304201703/http://www.un.org/apps/news/story.asp?NewsID=26857 |archive-date=2016年3月4日  }}</ref>。

===筛檢===
<!--{{main|肺癌篩檢}}-->
{{link-en|肺癌篩檢|Cancer screening}}乃在没有症状的人群中進行大規模{{link-en|医学检查|medical tests}}<ref>{{cite journal|title=Lung cancer screening|date=June 2013|journal=Seminars in Interventional Radiology|issue=2|doi=10.1055/s-0033-1342951|volume=30|pages=114–20|pmc=3709936|pmid=24436526|vauthors=Gutierrez A, Suh R, Abtin F, Genshaft S, Brown K}}</ref>。对有患肺癌高风险的人群可以通过[[X射线计算机断层成像|電腦斷層]]来筛查发现癌组织，也使病人有机会早期診斷並治療从而延长寿命<ref name="ACCPandATSfive"/><ref name="Us2016">{{cite journal|title=Screening for lung cancer: A systematic review and meta-analysis|date=August 2016|journal=Preventive Medicine|doi=10.1016/j.ypmed.2016.04.015|volume=89|pages=301–14|pmid=27130532|vauthors=Usman Ali M, Miller J, Peirson L, Fitzpatrick-Lewis D, Kenny M, Sherifali D, Raina P}}</ref>。这种形式的筛查使死于肺癌机率的{{tsl|en|Absolute risk reduction|絕對風險減少率|絕對風險}}减少了0.3%（{{tsl|en|Relative risk reduction|相對風險減少率|相對風險}}减少了20%）<ref>{{cite journal|title=The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups|date=July 2012|journal=Journal of Thoracic and Cardiovascular Surgery|issue=1|doi=10.1016/j.jtcvs.2012.05.060|volume=144|pages=33–38|pmid=22710039|vauthors=Jaklitsch MT, Jacobson FL, Austin JH, etal}}</ref><ref>{{cite journal|title=Benefits and harms of CT screening for lung cancer: a systematic review|date=June 2012|journal=JAMA: The Journal of the American Medical Association|issue=22|doi=10.1001/jama.2012.5521|volume=307|pages=2418–2429|pmc=3709596|pmid=22610500|vauthors=Bach PB, Mirkin JN, Oliver TK, etal}}</ref> 。高危人群是指那些年龄为55-74岁，抽烟量相当于连续30年每天1盒，而且戒烟不超过15年的人<ref name="ACCPandATSfive"/>。

電腦斷層{{tsl|en|False positives and false negatives|偽陽性率及偽陰性率|偽陽性率}}高，可能导致采取不必要的治疗措施<ref name="Ab2013">{{cite journal|title=Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial|date=March 2013|journal=Journal of Clinical Oncology|issue=8|doi=10.1200/JCO.2012.43.3110|volume=31|pages=1002–8|pmc=3589698|pmid=23401434|vauthors=Aberle DR, Abtin F, Brown K}}</ref>。被篩檢為陽性者，僅有1/20為偽陰性<ref>{{cite journal|title=Benefits and harms of CT screening for lung cancer: a systematic review|date=June 2012|journal=JAMA|issue=22|doi=10.1001/jama.2012.5521|volume=307|pages=2418–29|pmc=3709596|pmid=22610500|vauthors=Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC}}</ref>。偽陽性率高所衍生的公衛議題包含會造成額外的[[游離輻射|輻射暴露]]<ref name=Ab2013/>，且後續檢查也可能造成不必要的花費<ref name="ACCPandATSfive"/>。目前{{tsl|en|sputum|痰液|}}{{tsl|en|cytopathology|細胞病理學|細胞篩檢}}和{{tsl|en|chest radiograph|胸部影像學|胸部X光}}等另外兩種篩檢沒有任何已知效益<ref name=Us2016/><ref>{{cite journal|title=Screening for lung cancer|date=June 2013|journal=The Cochrane Database of Systematic Reviews|issue=6|doi=10.1002/14651858.CD001991.pub3|volume=6|pages=CD001991|pmid=23794187|vauthors=Manser R, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D}}</ref>。

{{link-en|美国预防服务工作组|United States Preventive Services Task Force}}（USPSTF）建议对那些每年抽菸超過30包，且年龄介于55-80歲之间的人每年用低剂量CT筛查肺癌直到他们停止吸烟超过15年<ref name="Moy2014">{{cite journal|title=Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement|date=March 2014|journal=Annals of Internal Medicine|issue=5|doi=10.7326/M13-2771|volume=160|pages=330–8|pmid=24378917|vauthors=Moyer VA}}</ref>。對於因有其它健康问题

此CT筛查不适用于那些有或即使发现患肺癌后也无法治疗的人<ref name="Moy2014"/>。2014年，{{link-en|英国国家卫生署|National Health Service (England)}}重新审查了支持进行CT筛查的证据<ref>{{cite journal|title=Lung cancer screening with low dose computed tomography|date=March 2014|journal=BMJ|doi=10.1136/bmj.g1970|volume=348|pages=g1970|pmid=24609921|vauthors=Baldwin DR, Hansell DM, Duffy SW, Field JK}}</ref>。

===其他预防措施===
长期补充[[维生素A|维生素A]]<ref name="Fabricius">{{cite journal | vauthors = Fabricius P, Lange P | title = Diet and lung cancer | journal = Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace | volume = 59 | issue = 3 | pages = 207–11 | date = July–September 2003 | pmid = 15065316 }}</ref><ref>{{cite journal | vauthors = Fritz H, Kennedy D, Fergusson D, Fernandes R, Doucette S, Cooley K, Seely A, Sagar S, Wong R, Seely D | title = Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis | journal = PLOS One | volume = 6 | issue = 6 | pages = e21107 | year = 2011 | pmid = 21738614 | pmc = 3124481 | doi = 10.1371/journal.pone.0021107 }} {{open access}}</ref>、[[维生素C|C]]<ref name="Fabricius" />、[[维生素D|D]]<ref>{{cite journal | vauthors = Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkina T, Branscheidt M, Eschmann R, Bals R | title = The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer | journal = Respiratory Research | volume = 12 | issue = 1 | pages = 31 | date = March 2011 | pmid = 21418564 | pmc = 3071319 | doi = 10.1186/1465-9921-12-31 }}</ref>或[[维生素E|E]]<ref name="Fabricius" />并不会降低患肺癌的风险。一些研究表明：饮食中蔬菜和水果比例较高的人患肺癌风险似乎更低<ref name="Alberg" /><ref name="Key">{{cite journal | vauthors = Key TJ | title = Fruit and vegetables and cancer risk | journal = British Journal of Cancer | volume = 104 | issue = 1 | pages = 6–11 | date = January 2011 | pmid = 21119663 | pmc = 3039795 | doi = 10.1038/sj.bjc.6606032 }}</ref>，但这也可能混杂了其他{{tsl|en|confounding|混擾|混擾因子}}，因為會吃蔬果的人可能會抽菸的比例也較低。目前还未有严谨的调查研究证明饮食和肺癌风险之间有明确关联<ref name="Harrison" /><ref name="Key" />，但有芸萃分析支持抽菸者如果配合健康飲食可以降低肺癌風險<ref>{{cite journal | vauthors = Sun Y, Li Z, Li J, Li Z, Han J | title = A Healthy Dietary Pattern Reduces Lung Cancer Risk: A Systematic Review and Meta-Analysis | journal = Nutrients | volume = 8 | issue = 3 | pages = 134 | date = March 2016 | pmid = 26959051 | pmc = 4808863 | doi = 10.3390/nu8030134 }}</ref>。

==治療==
<!--{{main|肺癌的治疗}}-->
肺癌的治疗取决于癌细胞的类型，[[肺癌分期|扩散程度]]和病人的身体状况。通常的治疗措施包括：[[和缓医疗|和缓医疗]]<ref>{{cite journal | vauthors = Ferrell B, Koczywas M, Grannis F, Harrington A | title = Palliative care in lung cancer | journal = The Surgical Clinics of North America | volume = 91 | issue = 2 | pages = 403–17, ix | date = April 2011 | pmid = 21419260 | pmc = 3655433 | doi = 10.1016/j.suc.2010.12.003 }}</ref>、[[手术|手术]]，[[化疗|化疗]]和[[放疗|放疗]]<ref name="Harrison" />。对晚期肺癌来说，{{tsl|en|Targeted therapy of lung cancer|肺癌的標靶治療|標靶治療}}会变得越来越重要。

===手术===
<!--{main|肺癌手术}}-->
[[Image:Lung_cancer.jpg|thumb]]，生長於支气管附近。]]

如果确诊为非小细胞肺癌，对其进行[[肺癌分期|分期]]可确定肺癌病灶是否为局限性、能否手术切除，或是否癌组织已扩散到无法用手术治疗的程度，这可用CT和正电子成像术（[[正电子发射计算机断层扫描|PET]]）扫描来决定<ref name="Harrison" />。如果怀疑纵膈淋巴结受累可以取样淋巴结从而协助分期。取樣技術包含經胸壁穿刺針吸活檢術（transthoracic needle aspiration）、经支气管针吸活检（transbronchial needle aspiration，可選擇是否要用氣管內視鏡超音波輔助）、{{tsl|en|endoscopic ultrasound|內視鏡超音波|}}細針抽吸、{{link-en|纵膈镜检|mediastinoscopy}}、{{tsl|en|thoracoscopy|胸腔鏡|}}<ref>{{cite book|title=Fishman's Pulmonary Diseases and Disorders|publisher=McGraw-Hill|year=2015|isbn=978-0-07-179672-9|edition=5th|page=1728|chapter=Chapter 112: Clinical evaluation, diagnosis, and staging of lung cancer|vauthors=Chang L, Rivera MP|veditors=Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM}}</ref>。[[血液检查|血液检查]]和{{link-en|肺功能检查|pulmonary function testing}}可用于评估病人能否承受手术<ref name="Collins" />。如果肺功能检查发现病人呼气储备量很低可能不会进行手术<ref name="Harrison" />。

对大多数早期的非小细胞肺癌患者手术会选择只切除一个肺叶（{{link-en|肺叶切除术|lobectomy|}}）。对于不适合行完整肺叶切除术的病人，可能可沿邊緣將含有腫瘤的三角形區域切除（{{link-en|楔形切除术|wedge resection}}）。但是与肺叶切除术相比楔形切除术术后更易复发<ref name="Fishman1855">{{Cite book|title=Fishman's Pulmonary Diseases and Disorders|author=Kaiser LR|publisher=McGraw-Hill|year=2008|isbn=0-07-145739-9|edition=4th|pages=1855–1856}}</ref>。在楔形切除部位的边缘进行[[近距离治疗|近距离]]放射[[碘|碘]]治療（Radioactive iodine brachytherapy）可能会降低复发的风险<ref>{{cite journal|title=Sublobar resection with brachytherapy mesh for stage I non-small cell lung cancer|last=Odell|first=DD|date=2010-01-03|journal=Seminars in Thoracic and Cardiovascular Surgery|issue=1|doi=10.1053/j.semtcvs.2010.04.003|volume=22|pages=32–37|pmid=20813314|author3=Fernando HC|author2=Kent MS}}</ref>。僅有在相當罕見的情況下才會進行{{tsl|en|pneumonectomy|全肺切除术|}}<ref>{{Cite book|title=Fishman's Pulmonary Diseases and Disorders|publisher=McGraw-Hill|year=2015|isbn=978-0-07-179672-9|edition=5th|pages=1737–1738|chapter=Chapter 113: Treatment of non-small-cell lung cancer: surgery|vauthors=Reznik SI, Smythe WR|veditors=Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM}}</ref>。{{tsl|en|Video-assisted thoracoscopic surgery|电视辅助胸腔镜手术|}}（VATS）和{{tsl|en|VATS lobectomy|VATS肺叶切除术|}}使用微创技术对肺癌进行手术治疗<ref>{{cite journal|title=Video-assisted thoracic surgery (VATS) lobectomy: the evidence base|date=July–September 2007|journal=Jsls|issue=3|volume=11|pages=368–74|pmc=3015831|pmid=17931521|vauthors=Alam N, Flores RM}}</ref>。与传统的开放肺叶切除术相比VATS肺叶切除术同样有效且术后并发症更少<ref>{{cite journal|title=Is VATS lobectomy better: perioperatively, biologically and oncologically?|date=June 2010|journal=The Annals of Thoracic Surgery|issue=6|doi=10.1016/j.athoracsur.2010.03.020|volume=89|pages=S2107–11|pmid=20493991|vauthors=Rueth NM, Andrade RS}}</ref>。

小细胞肺癌通常使用化疗和/或放疗<ref name="SimonTurrisi">{{cite journal|title=Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)|url=http://chestjournal.chestpubs.org/content/132/3_suppl/324S.long|date=September 2007|journal=Chest|issue=3 Suppl|doi=10.1378/chest.07-1385|volume=132|pages=324S-339S|pmid=17873178|vauthors=Simon GR, Turrisi A}}</ref>，但是人们正重新考量手术对小细胞肺癌的作用。對於沒有遠端轉移且無進犯縱膈者，可以先以外科手術切除，再進行輔助性化療<ref name="NCCN2018">{{Cite web|url=https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf|title=NCCN Guidelines 2018 - Small Cell Lung Cancer|accessdate=2018-04-08|author=National Comprehensive Cancer Network|date=2018-01-17|publisher=}}</ref>。而對於已經進犯縱膈腔者，則建議先以化放療作為初始治療<ref name="NCCN2018" />。

===放疗===
[[File:Diagram_showing_how_you_have_internal_radiotherapy_for_lung_cancer_CRUK_160_zh.svg|thumb]]化疗通常和[[放疗|放疗]]同时进行，对于不符合手术条件的非小细胞肺癌患者，放疗也可用于根治性治疗。这种高强度的放疗被称为根治性放疗<ref name="OTO" />。连续超分割加速放疗（CHART）是对根治性放疗的改进，它在短时间内给予患者大剂量的放疗<ref>{{cite journal|title=Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions|date=June 2010|journal=Clinical Oncology|issue=5|doi=10.1016/j.clon.2010.03.010|volume=22|pages=356–64|pmid=20399629|vauthors=Hatton MQ, Martin JE}}</ref>。非小细胞肺癌行治疗目的的手术后一般不應進行胸部放疗<ref name="PORT Meta-analysis Trialists Group" />，但对有纵膈N2淋巴结累及的一些患者来说术后放疗可能有好处<ref>{{cite journal|title=Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data|journal=The Oncologist|issue=5|doi=10.1634/theoncologist.2010-0150|year=2011|volume=16|pages=672–81|pmc=3228187|pmid=21378080|vauthors=Le Péchoux C}}</ref>。对可能治癒的小细胞肺癌患者化疗之外通常建议进行胸部放疗<ref name="Holland-Frei78" />。

如果癌组织堵塞了一小段支气管，可以在气道内用[[近距离治疗|近距离治疗]]（局部放疗）直接打通。和体外放射治疗相比,近距离治疗可减少治疗时间，也可减少对医护人员的射线照射量<ref>{{Cite journal|title=Radiation therapy: state of the art and the future|author=|url=https://www.jstage.jst.go.jp/article/jmi/57/1,2/57_1,2_1/_article|last=Ikushima|first=Hitoshi|date=2010|journal=The Journal of Medical Investigation|issue=1,2|doi=10.2152/jmi.57.1|others=|year=|volume=57|page=|pages=1–11|language=|issn=1349-6867|pmid=20299738}}</ref>。然而目前近距離治療的相關治療證據，仍比傳統的体外放射治疗要少<ref>{{cite journal|title=Palliative endobronchial brachytherapy for non-small cell lung cancer|date=December 2012|journal=The Cochrane Database of Systematic Reviews|doi=10.1002/14651858.CD004284.pub3|volume=12|pages=CD004284|pmid=23235606|vauthors=Reveiz L, Rueda JR, Cardona AF}}</ref>。

{{link-en|预防性颅脑照射|Prophylactic cranial irradiation}}（PCI）是脑部的一种放疗手段，用于降低肿瘤[[癌症转移|转移]]风险，对小细胞肺癌最有用。PCI使局限期肺癌的三年生存率從15%提升至20%，使广泛期肺癌的一年生存率從13%增加至27%<ref>{{cite journal|title=Prophylactic cranial irradiation in lung cancer|date=June 2011|journal=Cancer Treatment Reviews|issue=4|doi=10.1016/j.ctrv.2010.08.009|volume=37|pages=261–5|pmid=20934256|vauthors=Paumier A, Cuenca X, Le Péchoux C}}</ref>。

近年来靶向治疗和影像技术的改进使立体定向放疗治疗早期肺癌这一疗法得到发展。这种放疗方法使用立体定向定位技术分几次对病人进行大剂量放疗。这最初用于那些由于某些{{link-en|合并症|comorbidities}}无法进行手术的患者<ref>{{cite journal|title=[Stereotactic radiotherapy for non-small cell lung cancer: From concept to clinical reality. 2011 update]|date=October 2011|journal=Cancer Radiotherapie|issue=6–7|doi=10.1016/j.canrad.2011.07.241|volume=15|pages=522–6|pmid=21889901|vauthors=Girard N, Mornex F}}</ref>。

对非小细胞肺癌和小细胞肺癌患者来说稍小剂量的胸部放疗可用于控制症状（和緩性放療）<ref>{{Cite journal|title=Palliative thoracic radiotherapy for lung cancer: a systematic review|url=http://jco.ascopubs.org/content/26/24/4001.full|date=August 2008|journal=Journal of Clinical Oncology|issue=24|doi=10.1200/JCO.2007.15.3312|volume=26|pages=4001–4011|pmid=18711191|archiveurl=https://web.archive.org/web/20130413233918/http://jco.ascopubs.org/content/26/24/4001.full|archivedate=2013-04-13|deadurl=no|vauthors=Fairchild A, Harris K, Barnes E, etal}}</ref>。{{link-en|射频消融术|Radiofrequency ablation}}是一种利用高频[[电流|电流]]来杀死肿瘤细胞的新技术，可以用于肿瘤病灶较小的早期患者或放疗后的复发患者。这是一种创伤较小的治疗手段，较开胸手术而言，可以尽可能多地保护肺功能，适用于无法手术的患者<ref name="Merck"/>。

===化疗===
[[化疗|化疗]]方案取决于肿瘤类型<ref name="Holland-Frei78" />。小细胞肺癌（SCLC）即使在相对早期也主要采用化疗和放疗进行治疗<ref>{{cite journal|title=Management of small-cell lung cancer: incremental changes but hope for the future|date=2008-11-30|journal=Oncology (Williston Park)|issue=13|volume=22|pages=1486–92|pmid=19133604|vauthors=Hann CL, Rudin CM}}</ref>，常用的化疗方案为[[依托泊苷|依托泊苷]]联合一种铂类药物（顺铂或卡铂）<ref name="Murray" />，二者也常和[[卡铂|卡铂]]、[[吉西他滨|吉西他滨]]、[[紫杉醇|紫杉醇]]、{{link-en|长春瑞滨|vinorelbine}}、[[拓扑替康|拓扑替康]]、[[伊立替康|伊立替康]]等药物联用<ref name="Azim" /><ref name="MacCallum" />。对于晚期非小细胞肺癌（NSCLC），如果病人身体可承受，化疗可提高存活率，為第一线治疗手段<ref name="pmid18678835">{{cite journal|title=Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials|date=October 2008|journal=J. Clin. Oncol.|issue=28|doi=10.1200/JCO.2008.17.7162|volume=26|pages=4617–25|pmc=2653127|pmid=18678835|author1=NSCLC Meta-Analyses Collaborative Group}}</ref>，并且通常使用两种药物来治疗，其中一种常为铂类（顺铂或卡铂）。其它常用的化疗药物为：[[吉西他滨|吉西他滨]]、[[紫杉醇|紫杉醇]]、[[多西他赛|多西他赛]]<ref>{{Cite book|title=Fishman's Pulmonary Diseases and Disorders|publisher=McGraw-Hill|year=2015|isbn=978-0-07-179672-9|edition=5th|page=1752|chapter=Chapter 114: Treatment of non-small-cell lung cancer: chemotherapy|vauthors=Carr LL, Jett JR|veditors=Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM}}</ref><ref name="Clegg" />、{{link-en|培美曲塞|pemetrexed}}<ref name="pmid20446853">{{cite journal|title=Pemetrexed in advanced non-small-cell lung cancer|date=June 2010|journal=Expert Opin Pharmacother|issue=8|doi=10.1517/14656566.2010.482560|volume=11|pages=1387–402|pmid=20446853|vauthors=Fuld AD, Dragnev KH, Rigas JR}}</ref>、[[依托泊苷|依托泊苷]]或{{link-en|长春瑞滨|vinorelbine}}<ref name="Clegg" />。70歲以上的患者如果使用铂类药物進行化療，其產生嚴重副作用的風險會較高<ref>{{cite journal|title=Chemotherapy for advanced non-small cell lung cancer in the elderly population|date=October 2015|journal=The Cochrane Database of Systematic Reviews|issue=10|doi=10.1002/14651858.CD010463.pub2|pages=CD010463|pmid=26482542|vauthors=Santos FN, de Castria TB, Cruz MR, Riera R}}</ref>。

{{link-en|辅助化疗|Adjuvant therapy}}是指在進行根除型手术後再实施化疗，目的是提高疗效。对于非小细胞肺癌，手术过程中会在病灶旁[[淋巴結|淋巴结]]取样以辅助[[肺癌分期|分期]]。如果确定其为肺癌II或III期，辅助性化疗可以使五年生存率提高4%<ref name="Carbone">{{cite journal|title=Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms|date=September 2011|journal=Clinical Lung Cancer|issue=5|doi=10.1016/j.cllc.2011.06.002|volume=12|pages=261–71|pmid=21831720|vauthors=Carbone DP, Felip E}}</ref><ref name="Le Chevalier">{{cite journal|title=Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?|url=http://annonc.oxfordjournals.org/content/21/suppl_7/vii196.long|date=October 2010|journal=Annals of Oncology|issue=Suppl. 7|doi=10.1093/annonc/mdq376|volume=21 Suppl 7|pages=vii196-8|pmid=20943614|vauthors=Le Chevalier T}}</ref><ref>{{cite journal|title=Adjuvant chemotherapy for resected early-stage non-small cell lung cancer|date=March 2015|journal=The Cochrane Database of Systematic Reviews|issue=3|doi=10.1002/14651858.CD011430|pages=CD011430|pmid=25730344|display-authors=6|vauthors=Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y}}</ref> 。与旧的化疗方案相比，长春瑞滨和顺铂联用更有效<ref name="Le Chevalier" />。对IB期肺癌是否应采用辅助性化疗还有争议，因为[[临床试验|临床试验]]还未证明其可以提高生存率<ref>{{cite journal|title=Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis|date=June 2015|journal=Medicine|issue=22|doi=10.1097/MD.0000000000000903|volume=94|pages=e903|pmc=4616365|pmid=26039122|vauthors=He J, Shen J, Yang C, Jiang L, Liang W, Shi X, Xu X, He J}}</ref>。非小细胞肺癌的癌组织若能手术切除，{{link-en|术前化疗|Chemotherapy before surgery}}也能提高疗效<ref>{{cite journal|title=Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data|date=May 2014|journal=Lancet|issue=9928|doi=10.1016/S0140-6736(13)62159-5|volume=383|pages=1561–71|pmc=4022989|pmid=24576776|vauthors=}}</ref><ref>{{cite journal|title=Chemotherapy and surgery versus surgery alone in non-small cell lung cancer|date=July 2007|journal=The Cochrane Database of Systematic Reviews|issue=3|doi=10.1002/14651858.CD006157.pub2|pages=CD006157|pmid=17636828|vauthors=Burdett SS, Stewart LA, Rydzewska L}}</ref>。

在对非小细胞肺癌的治疗中，化疗可能会与和缓医疗联合应用。对晚期病人而言，适当的化疗比单纯的支持性护理更能提高平均存活率，也可以改善生存质量<ref name="pmid7551923">{{cite journal|title=Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer|date=April 1995|journal=Lung Cancer|issue=|doi=10.1016/0169-5002(95)00430-9|volume=12 Suppl 1|pages=S147–54|pmid=7551923|vauthors=Souquet PJ, Chauvin F, Boissel JP, Bernard JP}}</ref><ref>{{Cite journal|title=Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer|url=https://www.ncbi.nlm.nih.gov/pubmed/20464750|last=Non-Small Cell Lung Cancer Collaborative Group|date=2010-05-12|journal=The Cochrane Database of Systematic Reviews|issue=5|doi=10.1002/14651858.CD007309.pub2|pages=CD007309|issn=1469-493X|pmid=20464750}}</ref>。在和缓医疗的过程中如果病人身体状况允许的话，持續化疗可以使存活时间延长1.5到3个月，也可减轻症状，改善生存质量，且现代化疗药物的效果更好<ref name="pmid11441939">{{cite journal|title=A systematic overview of chemotherapy effects in non-small cell lung cancer|journal=Acta Oncologica|issue=2–3|doi=10.1080/02841860151116402|year=2001|volume=40|pages=327–39|pmid=11441939|vauthors=Sörenson S, Glimelius B, Nygren P}}</ref><ref name="pmid12065068">{{cite journal|title=A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer|url=http://wrap.warwick.ac.uk/52130/|journal=Health Technology Assessment|issue=32|year=2001|volume=5|pages=1–195|pmid=12065068|archiveurl=https://web.archive.org/web/20170830234842/http://wrap.warwick.ac.uk/52130/|archivedate=2017-08-30|deadurl=no|vauthors=Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N}}</ref>。非小细胞肺癌[[芸萃分析|芸萃分析]]协作小组建议：在晚期非小细胞肺癌的治疗中，如果患者願意而且可忍受就应该考虑进行化疗<ref name="pmid18678835" /><ref name="pmid20464750">{{cite journal|title=Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer.|first1=Group|date=2010-05-12|journal=The Cochrane Database of Systematic Reviews|issue=5|doi=10.1002/14651858.CD007309.pub2|pages=CD007309|pmid=20464750|last1=Non-Small Cell Lung Cancer Collaborative}}</ref>。

===標靶治療===

肺癌、特别是在晚期肺癌的治疗中，有几种{{tsl|en|targeted therapy of lung cancer|肺癌的標靶治療|以分子路径为靶标的药物}}可用。[[厄洛替尼|厄洛替尼]] 、[[吉非替尼|吉非替尼]]，和[[阿法替尼|阿法替尼]]抑制[[表皮生长因子受体|表皮生长因子受体]]中的[[酪氨酸激酶|酪氨酸激酶]]。{{link-en|地诺单抗|Denosumab}}是針對[[RANKL|RANKL]]的[[单克隆抗体|单克隆抗体]]，本品會與RANKL結合，使其無法激活{{tsl|en|osteoclast|蝕骨細胞|}}，对治疗骨转移癌有效<ref>{{cite journal|title=Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies|date=May 2014|journal=Therapeutic Advances in Medical Oncology|issue=3|doi=10.1177/1758834014521110|volume=6|pages=101–14|pmc=3987652|pmid=24790650|vauthors=D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F}}</ref>。2015年单克隆抗体药物[[安维汀|安维汀]]（贝伐珠单抗）肺癌适应症在中国上市，其通过抑制[[肿瘤|肿瘤]][[血管生成|血管生成]]来治疗癌症<ref>{{cite web|title=安维汀正式在华上市 将为中国患者打开希望之门|accessdate=2015-08-09|url=http://news.21cn.com/caiji/roll1/a/2015/0803/19/29877301.shtml|archiveurl=https://web.archive.org/web/20151002051252/http://news.21cn.com/caiji/roll1/a/2015/0803/19/29877301.shtml|archivedate=2015-10-02|deadurl=yes}}</ref>。

[[T细胞|T细胞]]上的[[受体_(生物化学)|受体]]{{tsl|en|CTLA-4}}会抑制免疫系统，有些癌細胞便會依此機制來逃脫免疫系統的偵查。{{tsl|en|Ipilimumab|伊匹单抗|}}（Ipilimumab）會抑制CTLA-4，藉此來阻断其[[訊息傳遞_(生物)|信号传导]]，減少癌細胞逃脫的機會，[[FDA|FDA]]已批准其用于治疗[[黑色素瘤|黑色素瘤]]。目前有第三期試驗顯示伊匹单抗與{{tsl|en|nivolumab|保疾伏}}（nivolumab）併用可以延長非小细胞肺癌的存活期<ref>{{Cite journal|title=Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden|url=https://doi.org/10.1056/NEJMoa1801946|last=Hellmann|first=Matthew D.|last2=Ciuleanu|first2=Tudor-Eliade|date=2018-04-16|journal=New England Journal of Medicine|issue=0|doi=10.1056/NEJMoa1801946|volume=0|pages=null|issn=0028-4793|pmid=29658845|last3=Pluzanski|first3=Adam|last4=Lee|first4=Jong Seok|last5=Otterson|first5=Gregory A.|last6=Audigier-Valette|first6=Clarisse|last7=Minenza|first7=Elisa|last8=Linardou|first8=Helena|last9=Burgers|first9=Sjaak}}</ref>。

{{link-en|程序性细胞死亡1|programmed cell death 1}}蛋白（PD-1）传导的信号可使T细胞失活，一些癌细胞會表达PD-L1，使T细胞無法作用。因此有些藥物藉由抑制PD-1与其[[配体_(生物化学)|配体]][[PD-1配体1|PD-1配体1]]（PD-L1）来发挥疗效，此類藥物已被批准作為某些肺癌的前幾線藥物<ref name="Syn2017" />。PD-1因此可使用PD-1和PD-L1的单克隆抗体來對況這些癌細胞。此類藥物包含{{link-en|派姆单抗|pembrolizumab}}（pembrolizumab）、{{tsl|en|nivolumab|保疾伏}}<ref name="Powell_2013" />、癌自禦（atezolizumab）<ref>{{cite journal|title=Update in lung cancer and mesothelioma 2012|first1=CA|last2=Halmos|first2=B|date=2013年7月|journal=American Journal of Respiratory and Critical Care Medicine|issue=2|doi=10.1164/rccm.201304-0716UP|volume=188|pages=157–166|pmc=3778761|pmid=23855692|last3=Nana-Sinkam|first3=SP|last1=Powell}}</ref>，以及{{Le|度伐魯單抗|durvalumab}}（durvalumab）等等<ref name="Syn2017" />，相關的临床试验目前正在进行<ref name="Syn2017" />。

有些肺癌患者已对表皮生长因子受体（EGFR）和{{link-en|间变性淋巴瘤激酶|anaplastic lymphoma kinase}}（ALK）的{{link-en|酪氨酸激酶抑制剂|Kinase tyrosine-based inhibitory motif}}產生耐受性，故有些新药正在開發中。新的EGFR抑制剂包括[[阿法替尼|阿法替尼]]和{{tsl|en|Dacomitinib|達科米替尼}}。<!-- 結果好像不太好，放這裡做參考 「{{tsl|en|tivantinib}}和{{tsl|en|onartuzumab}}则可抑制另一信号通路{{tsl|en|c-Met}}。」-->新的ALK抑制剂包括{{link-en|克里唑替尼|crizotinib}}（crizotinib）和{{link-en|色瑞替尼|ceritinib}}（ceritinib）<ref>{{cite journal|title=Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future|date=August 2014|journal=Frontiers in Oncology|issue=233|doi=10.3389/fonc.2014.00233|volume=4|pages=233|pmc=4145253|pmid=25221748|vauthors=Spaans JN, Goss GD}}</ref>。

=== 支氣管鏡 ===

對於氣道阻塞或流血的病人，有數種治療可透過支氣管鏡進行。如果氣管遭到腫瘤堵塞者，可以選擇的治療包含硬式支氣管鏡（rigid bronchoscopy）、支氣管內氣囊擴張和成形術（balloon bronchoplasty）、支架置放術，以及微型輕創術（microdebridement）等等<ref>{{cite book | vauthors = Lazarus DR, Eapen GA | title=Lung Cancer | publisher=Wiley-Blackwell | veditors = Roth JA, Hong WK, Komaki RU | year=2014 | chapter=Chapter 16: Bronchoscopic interventions for lung cancer | edition=4th | isbn=978-1-118-46874-6 }}</ref>。雷射燒灼術（Laser photosection）則需藉由支氣管鏡讓雷射進入氣道，並將堵塞的腫瘤移除<ref>{{cite journal | vauthors = Khemasuwan D, Mehta AC, Wang KP | title = Past, present, and future of endobronchial laser photoresection | journal = Journal of Thoracic Disease | volume = 7 | issue = Suppl 4 | pages = S380–8 | date = December 2015 | pmid = 26807285 | pmc = 4700383 | doi = 10.3978/j.issn.2072-1439.2015.12.55 }}</ref>。

===和缓医疗===
[[和缓医疗|和缓医疗]]能提升患者在治療期間的生活品質。即使正在進行常規化疗的患者，合併給予和緩醫療也有助益<ref>{{cite journal|title=Early specialty palliative care--translating data in oncology into practice|date=December 2013|journal=The New England Journal of Medicine|issue=24|doi=10.1056/nejmsb1305469|volume=369|pages=2347–51|pmc=3991113|pmid=24328469|vauthors=Parikh RB, Kirch RA, Smith TJ, Temel JS}}</ref>。和緩醫療也能夠給予患者和醫師雙方一段過渡期，以避免情急之下做出無法反悔的決定<ref name="pmid20818881">{{cite journal|title=Palliative care--a shifting paradigm|date=August 2010|journal=The New England Journal of Medicine|issue=8|doi=10.1056/NEJMe1004139|volume=363|pages=781–2|pmid=20818881|vauthors=Kelley AS, Meier DE}}</ref><ref name="pmid19856592">{{cite journal|title=When hospice is the best option: an opportunity to redefine goals|date=April 2009|journal=Oncology|issue=4 Suppl Nurse Ed|volume=23|pages=13–7|pmid=19856592|vauthors=Prince-Paul M}}</ref> 。和緩醫療並不只用於生命垂危之際，在整个病程中，和缓医疗都可以避免无用但昂贵的治疗措施。对那些癌症晚期的病人，則建議轉由[[安宁病房|安宁病房]]進行安寧療護<ref name="Collins" /><ref name="pmid19856592"/>。

==预后==
{| class="wikitable floatright" style="text-align:center;font-size:90%;width:35%;margin-left:1em"
|+ style="background:#E5AFAA;" |根据肺癌临床分期的治疗结果（AJCC第七版）<ref name="Rami-Porta" />
|- style="background: #E5AFAA;text-align:center;font-size:90%;"
! abbr="Type" rowspan="2" |临床分期
! abbr="5-year" colspan="2" | 五年以上存活率(%)
|- style="background: #E5AFAA;text-align:center;font-size:90%;"
! abbr="NSCLC" | 非小细胞肺癌
! abbr="SCLC" | 小细胞肺癌
|-
| IA
| 50
| 38
|-
| IB
| 47
| 21
|-
| IIA
| 36
| 38
|-
| IIB
| 26
| 18
|-
| IIIA
| 19
| 13
|-
| IIIB
| 7
| 9
|-
| IV
| 2
| 1
|}

美国所有肺癌患者中16.8%确诊后存活了至少5年<ref name="SEER" /><ref>{{cite journal|title=Epidemiology of lung cancer|date=June 2013|journal=Seminars in Interventional Radiology|issue=2|doi=10.1055/s-0033-1342949|volume=30|pages=93–8|pmc=3709917|pmid=24436524|vauthors=Ridge CA, McErlean AM, Ginsberg MS}}</ref>。在[[英格蘭|英格蘭]]和[[威爾士|威爾斯]]2010年到2011年之间肺癌总的五年生存率僅約有9.5%<ref>{{cite web|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/|title=Lung cancer survival statistics|publisher=Cancer Research UK|deadurl=no|archive-url=https://web.archive.org/web/20141007155320/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/|archive-date=2014年10月7日}}</ref>。[[发展中国家|发展中国家]]这一情况更糟糕<ref name="Maj2009"/>，确诊时往往已是晚期。就诊时30-40%的非小细胞肺癌已是Ⅳ期，60%的小细胞肺癌也已发展到Ⅳ期<ref name="Holland-Frei78" />。确诊时分期越晚，肺癌患者存活时间越短，英国的数据表明：确诊时处于最早期的病人中70%可以存活至少1年；但对那些确诊时处于最晚期的病人，这一数字下降到只有14%<ref>{{cite web|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/#stage|title=Lung cancer survival statistics|publisher=|access-date=2014年10月28日|deadurl=no|archive-url=https://web.archive.org/web/20141009015127/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/#stage|archive-date=2014年10月9日}}</ref>。

非小细胞肺癌的预后影响因素包括有无肺部症状、肿瘤大小（>3公分）、细胞类型（[[组织学|组织学]]）、扩散程度（[[癌症分期|分期]]）和是否[[遠端轉移|转移]]到多处[[淋巴结|淋巴结]]，有无{{tsl|en|vascular invasion|血管侵犯|}}。不能进行手术的病人中，身体状况差且体重下降超过10%者预后更差<ref name="AUTOREF17">{{cite web|url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/|title=Non-Small Cell Lung Cancer Treatment|accessdate=2015-11-17|work=PDQ for Health Professionals|publisher=National Cancer Institute|PMID=26389304}}</ref>。小细胞肺癌的预后影响因素包括：身体状况、性别、癌症分期，还有确诊时癌细胞是否累及[[中枢神经系统|中枢神经系统]]或者[[肝脏|肝脏]]<ref name="AUTOREF18" />。

对于非小细胞肺癌，若IA期时手术完整切除癌灶预后最好，多达70%患者可存活5年<ref name="OTM">{{Cite book|title=Oxford Textbook Medicine|publisher=OUP Oxford|year=2010|isbn=978-0-19-920485-4|edition=5th|chapter=18.19.1|vauthors=Spiro SG}}</ref>。小细胞肺癌的五年存活率总共约为5%<ref name="Harrison" />。晚期小细胞肺癌患者平均五年生存率不到1%。局限期患者的平均生存时间是20个月，五年生存率为20%<ref name="Merck" />。

根据[[美国国家癌症研究所|美国国家癌症研究所]]提供的数据，美国肺癌患者确诊时的年龄中位数为70岁<ref>SEER data (SEER.cancer.gov) [http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.11_2pgs.pdf Median Age of Cancer Patients at Diagnosis 2002–2003] {{webarchive|url=https://web.archive.org/web/20110516124412/http://seer.cancer.gov/csr/1975_2003/results_single/sect_01_table.11_2pgs.pdf|date=2011-05-16}}</ref>，死亡年龄中位数为72岁<ref>SEER data (SEER.cancer.gov) [http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.13_2pgs.pdf Median Age of Cancer Patients at Death 2002–2006] {{webarchive|url=https://web.archive.org/web/20110722134255/http://seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.13_2pgs.pdf|date=2011-07-22}}</ref>；有医疗保险的人可能预后更好<ref>{{cite journal|title=An official American Thoracic Society systematic review: insurance status and disparities in lung cancer practices and outcomes|url=http://ajrccm.atsjournals.org/content/182/9/1195.long|date=November 2010|journal=American Journal of Respiratory and Critical Care Medicine|issue=9|doi=10.1164/rccm.2009-038ST|volume=182|pages=1195–205|pmid=21041563|vauthors=Slatore CG, Au DH, Gould MK}}</ref>。

==流行病学==
[[File:Trachea, bronchus, lung cancers world map-Deaths per million persons-WHO2012.svg|upright=1.3|thumb|2012年，各國每100万居民死于气管癌、支气管癌、肺癌的年龄标准化数据。
{{refbegin|2}}{{legend|#ffff20|0–7}}{{legend|#ffe820|8–12}}{{legend|#ffd820|13–32}}{{legend|#ffc020|33–53}}{{legend|#ffa020|54–81}}{{legend|#ff9a20|82–125}}{{legend|#f08015|126–286}}{{legend|#e06815|287–398}}{{legend|#d85010|399–527}}{{legend|#d02010|528–889}}{{refend}}
]]
[[Image:Lung_cancer_US_distribution.gif|right]]白人男性罹患肺癌的地区分布]]
[[File:Lung_cancer,_incidence,_mortality_and_survival,_England_1971_-_2011.png|thumb]]1971到2011年间肺癌的发病率、死亡率和存活率]]
肺癌是全球男性最常見的癌症，也是發生率和死亡率最高的癌症。在女性則為發生率第三高的癌症，而死亡率則仅次于[[乳癌|乳癌]]，居第二位。2012年，全球肺癌新病例數約為182万，同時也有156万例死于肺癌，占了所有因癌症死亡人数的19.4%<ref name=WCR2014Epi/>。肺癌发病率最高的是北美、欧洲和东亚。2012年，超过三分之一的新增患者出现在中国大陸，而非洲和南亚肺癌发病率则要低得多<ref>{{cite book|title=World cancer report 2014|first1=edited by Bernard W.|last2=Wild|first2=Christopher P.|date=2014|publisher=IARC Press|isbn=9789283204299|location=Lyon|pages=350–352|last1=Stewart}}</ref>。在英国肺癌是第二大最常见癌症（2011年有大约43,500人被诊断为肺癌），也是癌症致死的最常见病因（2012年大约35,400人死于肺癌）<ref>{{cite web|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/|title=Lung cancer statistics|accessdate=2014-10-28|website=Cancer Research UK}}</ref>。

年龄超过50岁且有吸烟史的人群最可能罹患肺癌。和20多年前就开始下降的男性肺癌死亡率相比，女性的肺癌死亡率在过去数十年來不斷上升，最近才趋于稳定<ref name="AUTOREF22" />。<!-- now declining in US & Aus, WCR -->在美国，男性一生中患肺癌的[[累积发病率|风险]]是8%，女性是6%<ref name="Harrison" />。

據統計，約每抽掉300到400万根香烟，就有一个人死于肺癌<ref>{{cite journal|title=The history of the discovery of the cigarette-lung cancer link: evidentiary traditions, corporate denial, global toll|date=March 2012|journal=Tobacco Control|issue=2|doi=10.1136/tobaccocontrol-2011-050338|volume=21|pages=87–91|pmid=22345227|vauthors=Proctor RN}}</ref>。{{tsl|en|Big Tobacco|五大菸業}}的影响力在吸烟文化中发挥重要作用<ref name="Lum" />。看到烟草广告的年轻的非吸烟者更有可能开始吸烟<ref>{{cite journal | vauthors = Lovato C, Watts A, Stead LF | title = Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours | journal = The Cochrane Database of Systematic Reviews | issue = 10 | pages = CD003439 | date = October 2011 | pmid = 21975739 | doi = 10.1002/14651858.CD003439.pub2 }}</ref>。近年來，人们越来越重視[[被动吸烟|二手菸]]在誘發肺癌中的角色<ref name="Taylor" />，以致政府进行政策干预以减少非吸烟者不想要的暴露于其他人的烟草烟雾中的几率<ref>{{cite journal | vauthors = Kemp FB | title = Smoke free policies in Europe. An overview | journal = Pneumologia | volume = 58 | issue = 3 | pages = 155–8 | date = Jul–Sep 2009 | pmid = 19817310 }}</ref>。汽车、工厂、发电厂排放的废气也造成了潜在的风险<ref name="MurrayNadel52" />。

[[东欧|东欧]]男性的肺癌死亡率最高，而北欧和美国女性的肺癌死亡率最高。美国黑人男性和女性的发病率都更高<ref>{{cite web|publisher=National Cancer Institute|title=SEER stat fact sheets: Lung and Bronchus. Surveillance Epidemiology and End Results|year=2010|url=http://seer.cancer.gov/statfacts/html/lungb.html#incidence-mortality}}</ref>。目前在開發中國家，肺癌的發生率相對較低<ref name="AUTOREF23" />，但隨著這些國家的吸菸人口逐漸上升，肺癌的發生率在接下來的幾年可能會逐漸上升，特別是中國<ref>{{cite journal | vauthors = Zhang J, Ou JX, Bai CX | title = Tobacco smoking in China: prevalence, disease burden, challenges and future strategies | journal = Respirology | volume = 16 | issue = 8 | pages = 1165–72 | date = November 2011 | pmid = 21910781 | doi = 10.1111/j.1440-1843.2011.02062.x }}</ref>和印度<ref name="AUTOREF25" />。

在美國，老兵的肺癌發生率較其他族群要高出了25–50%，可能肇因於其抽菸比率較高<ref>{{cite web|title=HONORING VETERANS WITH GOOD HEALTH|url=http://gibbscancercenter.org/news/honoring-veterans-good-health/|accessdate=2015-12-01|date=2014-11-07|deadurl=yes|archiveurl=https://web.archive.org/web/20151128063005/http://gibbscancercenter.org/news/honoring-veterans-good-health/|archivedate=2015-11-28}}</ref>。也可能是在二戰和韓戰期間暴露於[[石棉|石棉]]當中，或在越戰中有遭受[[橘劑|橘劑]]暴露<ref>{{cite web|title=Lung Cancer As It Affects Veterans And Military|url=http://www.lungcanceralliance.org/special-features/special-focus-on-veterans-and-lung-cancer/lung-cancer-and-wartime-exposure.html|accessdate=2015-12-01|deadurl=yes|archiveurl=https://web.archive.org/web/20151208170738/http://www.lungcanceralliance.org/special-features/special-focus-on-veterans-and-lung-cancer/lung-cancer-and-wartime-exposure.html|archivedate=2015-12-08}}</ref>。

肺癌為英國第三常見的癌症（2014年約有46,400人新診斷肺癌）<ref>{{cite web | title=Cancer incidence statistics | url=http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One | website=Cancer Research UK | accessdate=2016-12-20 | deadurl=no | archiveurl=https://web.archive.org/web/20170102165540/http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence#heading-One | archivedate=2017-01-02 }}</ref>，且也是最常見的致死癌症（2014年約有35,900人死於肺癌）<ref>{{cite web | title=Lung cancer statistics | url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/ | website=Cancer Research UK | accessdate=2016-12-20 | deadurl=no | archiveurl=https://web.archive.org/web/20150512144023/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/ | archivedate=2015-05-12 }}</ref>。

在[[中国大陆|中国大陆]]，肺癌确诊后存活过5年的病人不足五分之一，中国大陆采用疗法的普遍有效程度虽然高于[[发展中国家|发展中国家]]的平均水平，但是显著低于[[日本|日本]]、[[韩国|韩国]]等发达国家，而且也低于例如[[乳癌|乳癌]]、[[结直肠癌|结直肠癌]]等其它癌症在中国大陆的疗效水平。<ref>{{cite journal|title=Lung cancer molecular epidemiology in China: recent trends|author=Caicun, Zhou|doi=10.3978/j.issn.2218-6751.2014.09.01}}</ref>。在[[台湾|台湾]]，确诊后存活过5年的病人约占总确诊人数的15.9%，其中一半的人能活过13.2个月。<ref>{{cite journal|title=Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry|author1=Bing-Yen, Wang|author2=Jing-Yang Huang|author3= Ching-Yuan Cheng|author4=Ching-Hsiung Lin|author5=Jiunn- Liang Ko|author6=Yung-Po Liaw|doi=10.1097/JTO.0b013e31829ceba4}}</ref>

从1960年代开始，相对于其他类型肺癌，肺腺癌的发病率开始上升，部分原因是过滤嘴香烟的面世。过滤嘴过滤掉了烟草中的大颗粒物，因此减少了大气道中的沉积物。但是抽烟者必须吸得更深以获得等量的[[尼古丁|尼古丁]]，因此沉积在小气道的颗粒物就增加了，而小氣道正是肺腺癌易发部位<ref name="Charloux" />。肺腺癌的发病率还在持续上升<ref>{{cite journal|title=Pulmonary adenocarcinoma: a renewed entity in 2011|date=January 2012|journal=Respirology|issue=1|doi=10.1111/j.1440-1843.2011.02095.x|volume=17|pages=50–65|pmid=22040022|vauthors=Kadara H, Kabbout M, Wistuba II}}</ref>。

==历史==
在吸菸普及之前，肺癌其實並不常見；在1761年之前，人们甚至不认为肺癌是一个明确的疾病<ref name="AUTOREF27" />。肺癌的各个方面在1810年得以详细记述<ref name="AUTOREF28" />。在1878年，尸检时发现的癌症中恶性肺肿瘤仅占1%，但到20世纪早期，这一比例已上升到10-15%<ref name="Witschi" />。在1912年，全世界医学文献中的肺癌病例报告只有374例<ref name="AUTOREF29" />，但是一篇尸检的综述表明肺癌的发病率已经从1852年的0.3%上升到了1952年的5.66%<ref name="Grannis" />。1929年，[[德国|德国]]内科医生{{link-en|弗里茨·利金特|Fritz Lickint}}意识到了吸烟和肺癌的直接关联<ref name="Witschi" />，这导致了一场激进的[[納粹德國禁煙運動|反吸烟运动]]<ref name="Proctor" />。在1950年代发表的{{tsl|en|British Doctors Study|英國醫師研究|对英国医生吸烟和肺癌的研究}}结果，第一次为吸烟和肺癌之间的关联提供了确凿的流行病学证据<ref name="Doll" />。因此在1964年{{link-en|美国军医署|Surgeon General of the United States}}建议吸烟者戒烟<ref name="AUTOREF30" />。

至於肺癌與[[氡|氡氣]]之間的關聯性，則要從一群在[[萨克森自由州|萨克森州]]{{tsl|en|Schneeberg, Saxony|施內貝格 (薩克森)|施內貝格}}附近的[[厄尔士山脉|厄尔士山脉]]工作的礦工開始說起。該礦坑從1740年就开始开采[[银|银]]矿，这些矿富含[[铀|铀]]，也附带有[[镭|镭]]和氡气<ref name="Greaves" />。矿工中很多人患了肺部疾病，直到1870年代才意识到是肺癌<ref>{{cite journal|title=Lung cancer in the Schneeberg mines: a reappraisal of the data reported by Harting and Hesse in 1879|date=February 1993|journal=The Annals of Occupational Hygiene|issue=1|doi=10.1093/annhyg/37.1.5|volume=37|pages=5–14|pmid=8460878|vauthors=Greenberg M, Selikoff IJ}}</ref>。尽管发现了这些问题，但由于[[苏联|苏联]]对铀的需求，开采还是持续到了1950年代<ref name="Greaves" />。1960年代，氡被确认为肺癌的一个致病因素<ref>{{Cite journal|title=Radiation and cancer risk: a continuing challenge for epidemiologists|date=April 2011|journal=Environmental Health|issue=Suppl. 1|doi=10.1186/1476-069X-10-S1-S4|volume=10|pages=S4|pmc=3073196|pmid=21489214|vauthors=Samet JM}}</ref>。

用于治疗肺癌的{{link-en|全肺切除术|pneumonectomy}}，在1933年首次成功<ref name="AUTOREF32" />。姑息[[放疗|放疗]]从1940年代开始使用<ref name="Edwards" />，从1950年代开始使用根治性放疗，即尝试对那些处于肺癌早期但不适合手术治疗的病人使用更大的放射剂量<ref name="AUTOREF33" />。在1997年，连续超分割加速放疗法出现，这被认为是对传统的根治性放疗的改进<ref name="Saunders" />。对小细胞肺癌，1960年代开始尝试手术切除<ref name="AUTOREF34" />和根治性放疗<ref name="AUTOREF35" />，但並不成功。至1970年代才开发出了成功的化疗方案<ref name="AUTOREF36" />。

==研究方向==
当前肺癌治疗的研究方向包括[[免疫治疗|免疫治疗]]（激活机体免疫系统攻击肿瘤细胞）<ref name=Syn2017>{{cite journal | vauthors = Syn NL, Teng MW, Mok TS, Soo RA | title = De-novo and acquired resistance to immune checkpoint targeting | journal = The Lancet. Oncology | volume = 18 | issue = 12 | pages = e731–e741 | date = December 2017 | pmid = 29208439 | doi = 10.1016/s1470-2045(17)30607-1 | url = http://linkinghub.elsevier.com/retrieve/pii/S1470204517306071 }}</ref>、[[表观遗传学|表观遗传学]]、化疗和放疗新组合（单独或合併使用）。这些新的治疗措施中很多是通过{{tsl|en|immune checkpoint blockade|免疫關卡阻斷劑|阻斷免疫關卡}}，干扰癌细胞逃避[[免疫系统|免疫系统]]攻击的能力<ref name=Syn2017 />。

[[表观遗传学|表观遗传学]]是研究遺傳性基因修飾以及基因表達的學門。生物體在不改變DNA序列狀況下，可以藉由一些分子標籤改變基因的表現，而這類修飾常常具有遺傳性。针对这些分子标签的药物可以杀死癌细胞，研究显示非小細胞癌早期給予藥物阻斷多重分子標籤，可以在副作用更少的情形下殺死癌細胞<ref name="Epi">{{cite journal|title=New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer|date=May 2014|journal=Clinical Cancer Research|issue=9|doi=10.1158/1078-0432.ccr-13-2088|volume=20|pages=2244–8|pmc=4325981|pmid=24644000|vauthors=Forde PM, Brahmer JR, Kelly RJ}}</ref>。在对病人进行标准化治疗前给他们用这些药可以提高效果<ref name="Epi" />。相關的臨床研究正在進行中，期望能探知此類藥物對於人類肺癌的效果<ref name="Epi" />。开发中的藥物包含[[组蛋白脱乙酰酶抑制剂|组蛋白脱乙酰酶抑制剂]]和{{link-en|DNA甲基转移酶|DNA methyltransferase}}，前者包括[[丙戊酸|丙戊酸]]，{{link-en|伏立诺他|vorinostat}}（vorinostat）、{{tsl|en|belinostat|貝利司他}}（belinostat）、{{link-en|帕比司他|panobinostat}}（panobinostat）、{{link-en|恩替诺特|entinostat}}（entinostat）和{{link-en|罗醚酯肽|romidepsin}}（romidepsin）。後者則包括{{link-en|地西他滨|decitabine}}（decitabine）、{{link-en|氮杂胞苷|azacytidine}}（azacitidine）和[[肼屈嗪|肼屈嗪]]<ref name="Jakopovic" />。

TRACERx計畫正在观察非小细胞肺癌如何形成和发展，以及这些肿瘤如何变得对治疗耐受<ref name="Tracer">{{cite journal|title=Tracking genomic cancer evolution for precision medicine: the lung TRACERx study|date=July 2014|journal=PLoS Biology|issue=7|doi=10.1371/journal.pbio.1001906|volume=12|pages=e1001906|pmc=4086714|pmid=25003521|display-authors=6|vauthors=Jamal-Hanjani M, Hackshaw A, Ngai Y, Shaw J, Dive C, Quezada S, Middleton G, de Bruin E, Le Quesne J, Shafi S, Falzon M, Horswell S, Blackhall F, Khan I, Janes S, Nicolson M, Lawrence D, Forster M, Fennell D, Lee SM, Lester J, Kerr K, Muller S, Iles N, Smith S, Murugaesu N, Mitter R, Salm M, Stuart A, Matthews N, Adams H, Ahmad T, Attanoos R, Bennett J, Birkbak NJ, Booton R, Brady G, Buchan K, Capitano A, Chetty M, Cobbold M, Crosbie P, Davies H, Denison A, Djearman M, Goldman J, Haswell T, Joseph L, Kornaszewska M, Krebs M, Langman G, MacKenzie M, Millar J, Morgan B, Naidu B, Nonaka D, Peggs K, Pritchard C, Remmen H, Rowan A, Shah R, Smith E, Summers Y, Taylor M, Veeriah S, Waller D, Wilcox B, Wilcox M, Woolhouse I, McGranahan N, Swanton C}}</ref>。这一项目会观察来自850例非小细胞肺癌病人的肿瘤样本，这些病人处于确诊后、初次治疗后、治疗后、和复发后等各个时期<ref>[http://scienceblog.cancerresearchuk.org/2013/07/18/a-new-era-in-lung-cancer-research-the-tracerx-study/ TRACERx project, Cancer Research UK science blog] {{webarchive|url=https://web.archive.org/web/20141129023515/http://scienceblog.cancerresearchuk.org/2013/07/18/a-new-era-in-lung-cancer-research-the-tracerx-study/|date=2014-11-29}}</ref>。通过分析肿瘤发展不同阶段的样本，研究者们希望找出哪些变化能够加速肿瘤的生长，加强肿瘤对治疗的耐受性。该项目的结果能够帮助科学家和医生理解非小细胞肺癌，并且可能有助于发现治疗肺癌的新的手段<ref name="Tracer" />。

{{Le|嵌合抗原受體|Chimeric antigen receptor}}T細胞免疫療法（Chimeric Antigen Receptor T-Cell Immunotherapy）乃是先取得患者自身的T細胞後，在體外以基因工程的技術，使T細胞具有辨識癌細胞的能力後，再回輸到患者身上。被改造後的T細胞即稱為嵌合抗原受體T細胞（CAR-T），該療法在[[急性淋巴性白血病|急性淋巴性白血病]]（ALL）的治療方面取得了重大突破。目前也正在研究該療法在治療非小細胞肺癌以及[[間皮瘤|間皮瘤]]的潛力<ref>{{Cite journal|title=CAR T-cell therapy for lung cancer and malignant pleural mesothelioma|author=|url=https://www.ncbi.nlm.nih.gov/pubmed/28502785|last=Zeltsman|first=Masha|last2=Dozier|first2=Jordan|date=09 2017|journal=Translational Research: The Journal of Laboratory and Clinical Medicine|issue=|doi=10.1016/j.trsl.2017.04.004|others=|year=|volume=187|page=|pages=1–10|issn=1878-1810|pmc=5581988|pmid=28502785|last3=McGee|first3=Erin|last4=Ngai|first4=Daniel|last5=Adusumilli|first5=Prasad S.}}</ref>。

==參考文獻==
{{Clear}}
{{reflist|30em|refs=

<ref name="Honnorat">{{cite journal | vauthors = Honnorat J, Antoine JC | title = Paraneoplastic neurological syndromes | journal = Orphanet Journal of Rare Diseases | volume = 2 | issue = 1 | pages = 22 | date = May 2007 | pmid = 17480225 | pmc = 1868710 | doi = 10.1186/1750-1172-2-22 | url = http://www.ojrd.com/content/2/1/22 | publisher = BioMed Central | archive-url = https://web.archive.org/web/20070927213613/http://www.ojrd.com/content/2/1/22 | deadurl = no | archive-date = 2007年9月27日 }}</ref>

<ref name="ajcc">{{Cite book | first = Greene | last = Frederick L. | name-list-format = vanc | title=AJCC cancer staging manual | publisher=Springer-Verlag | location=Berlin | year=2002 | pages= | isbn=0-387-95271-3 |oclc= |doi= |access-date=}}</ref>

<ref name="Peto">{{Cite book | vauthors=Peto R, Lopez AD, Boreham J, etal | title=Mortality from smoking in developed countries 1950–2000: Indirect estimates from National Vital Statistics | publisher=Oxford University Press | year=2006 | url=http://www.ctsu.ox.ac.uk/~tobacco/ | isbn=0-19-262535-7 | deadurl=no | archive-url=https://web.archive.org/web/20070905151935/http://www.ctsu.ox.ac.uk/~tobacco/ | archive-date=2007年9月5日 }}</ref>

<ref name="Schick">{{cite journal | vauthors = Schick S, Glantz S | title = Philip Morris toxicological experiments with fresh sidestream smoke: more toxic than mainstream smoke | journal = Tobacco Control | volume = 14 | issue = 6 | pages = 396–404 | date = December 2005 | pmid = 16319363 | pmc = 1748121 | doi = 10.1136/tc.2005.011288 }}</ref>

<ref name="EPA radon">{{cite web | last=EPA | authorlink=United States Environmental Protection Agency | title=Radiation information: radon | publisher=EPA | date=February 2013 | url=http://www.epa.gov/rpdweb00/radionuclides/radon.html | deadurl=no | archive-url=https://web.archive.org/web/20090429130828/http://www.epa.gov/rpdweb00/radionuclides/radon.html | archive-date=2009年4月29日 }}</ref>

<ref name="NEJM-molecular">{{cite journal | vauthors = Herbst RS, Heymach JV, Lippman SM | title = Lung cancer | journal = The New England Journal of Medicine | volume = 359 | issue = 13 | pages = 1367–80 | date = September 2008 | pmid = 18815398 | doi = 10.1056/NEJMra0802714 | url = http://content.nejm.org/cgi/content/full/359/13/1367 | archive-url = https://web.archive.org/web/20080928073051/http://content.nejm.org/cgi/content/full/359/13/1367 | deadurl = no | archive-date = 2008年9月28日 }}</ref>

<ref name="Aviel-Ronen">{{cite journal | vauthors = Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS | title = K-ras mutations in non-small-cell lung carcinoma: a review | journal = Clinical Lung Cancer | volume = 8 | issue = 1 | pages = 30–8 | date = July 2006 | pmid = 16870043 | doi = 10.3816/CLC.2006.n.030 | publisher = Cancer Information Group }}</ref>

<ref name="Rosti">{{cite journal | vauthors = Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G | title = Small cell lung cancer | journal = Annals of Oncology | volume = 17 Suppl 2 | issue = Suppl. 2 | pages = ii5-10 | date = March 2006 | pmid = 16608983 | doi = 10.1093/annonc/mdj910 }}</ref>

<ref name="Seo">{{cite journal | vauthors = Seo JB, Im JG, Goo JM, Chung MJ, Kim MY | title = Atypical pulmonary metastases: spectrum of radiologic findings | journal = Radiographics | volume = 21 | issue = 2 | pages = 403–17 | date = 2001-03-01 | pmid = 11259704 | doi = 10.1148/radiographics.21.2.g01mr17403 | url = http://radiographics.rsnajnls.org/cgi/content/full/21/2/403 | archive-url = https://web.archive.org/web/20071011203717/http://radiographics.rsnajnls.org/cgi/content/full/21/2/403 | deadurl = no | archive-date = 2007年10月11日 }}</ref>

<ref name="Raz">{{cite journal | vauthors = Raz DJ, He B, Rosell R, Jablons DM | title = Bronchioloalveolar carcinoma: a review | journal = Clinical Lung Cancer | volume = 7 | issue = 5 | pages = 313–22 | date = March 2006 | pmid = 16640802 | doi = 10.3816/CLC.2006.n.012 }}</ref>

<ref name="Bhutan">{{cite news | vauthors = Pandey G | title=Bhutan's smokers face public ban | publisher=BBC | date=February 2005 | url=http://news.bbc.co.uk/2/hi/south_asia/4305715.stm | access-date=2007年9月7日 | deadurl=no | archive-url=https://web.archive.org/web/20080407045728/http://news.bbc.co.uk/2/hi/south_asia/4305715.stm | archive-date=2008年4月7日 }}</ref>

<ref name="OTO">{{Cite book | vauthors = Arriagada R, Goldstraw P, Le Chevalier T  | title=Oxford Textbook of Oncology | publisher=Oxford University Press | year=2002 | page=2094 | edition=2nd | isbn=0-19-262926-3 }}</ref>

<ref name="PORT Meta-analysis Trialists Group">{{cite journal | vauthors =  | title = Postoperative radiotherapy for non-small cell lung cancer | journal = The Cochrane Database of Systematic Reviews | issue = 2 | pages = CD002142 | date = April 2005 | pmid = 15846628 | doi = 10.1002/14651858.CD002142.pub2 | editor1-last = Rydzewska | editor1-first = Larysa }}</ref>

<ref name="Murray">{{cite journal | vauthors = Murray N, Turrisi AT | title = A review of first-line treatment for small-cell lung cancer | journal = Journal of Thoracic Oncology | volume = 1 | issue = 3 | pages = 270–8 | date = March 2006 | pmid = 17409868 | doi=10.1016/s1556-0864(15)31579-3}}</ref>

<ref name="Azim">{{cite journal | vauthors = Azim HA, Ganti AK | title = Treatment options for relapsed small-cell lung cancer | journal = Anti-Cancer Drugs | volume = 18 | issue = 3 | pages = 255–61 | date = March 2007 | pmid = 17264756 | doi = 10.1097/CAD.0b013e328011a547 }}</ref>

<ref name="MacCallum">{{cite journal | vauthors = MacCallum C, Gillenwater HH | title = Second-line treatment of small-cell lung cancer | journal = Current Oncology Reports | volume = 8 | issue = 4 | pages = 258–64 | date = July 2006 | pmid = 17254525 | doi = 10.1007/s11912-006-0030-8 }}</ref>

<ref name="Clegg">{{cite journal | vauthors = Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N | title = Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review | journal = Thorax | volume = 57 | issue = 1 | pages = 20–8 | date = January 2002 | pmid = 11809985 | pmc = 1746188 | doi = 10.1136/thorax.57.1.20 | publisher = BMJ Publishing Group }}</ref>

<ref name="AUTOREF18">{{cite web |title=Small Cell Lung Cancer Treatment |publisher=National Cancer Institute |url=http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional |work=PDQ for Health Professionals |year=2012 |access-date=2012年5月16日 |deadurl=no |archive-url=https://web.archive.org/web/20120513015218/http://cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional |archive-date=2012年5月13日  }}</ref>

<ref name="AUTOREF22">{{cite journal | vauthors = Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ | title = Cancer statistics, 2004 | journal = Ca | volume = 54 | issue = 1 | pages = 8–29 | year = 2004 | pmid = 14974761 | doi = 10.3322/canjclin.54.1.8 }}</ref>

<ref name="Lum">{{cite journal | vauthors = Lum KL, Polansky JR, Jackler RK, Glantz SA | title = Signed, sealed and delivered: "big tobacco" in Hollywood, 1927-1951 | journal = Tobacco Control | volume = 17 | issue = 5 | pages = 313–23 | date = October 2008 | pmid = 18818225 | pmc = 2602591 | doi = 10.1136/tc.2008.025445 | url = http://tobaccocontrol.bmj.com/cgi/content/full/17/5/313 | archive-url = https://web.archive.org/web/20090404085818/http://tobaccocontrol.bmj.com/cgi/content/full/17/5/313 | deadurl = no | archive-date = 2009年4月4日 }}</ref>

<ref name="AUTOREF23">{{cite web | title=Gender in lung cancer and smoking research | publisher=[[世界卫生组织|World Health Organization]] | year=2004 | url=http://www.who.int/gender/documents/en/lungcancerlow.pdf | format=PDF | access-date=2007年5月26日 | deadurl=no | archive-url=https://web.archive.org/web/20070614013951/http://www.who.int/gender/documents/en/lungcancerlow.pdf | archive-date=2007年6月14日 }}</ref>

<ref name="AUTOREF25">{{cite journal | vauthors = Behera D, Balamugesh T | title = Lung cancer in India | journal = The Indian Journal of Chest Diseases & Allied Sciences | volume = 46 | issue = 4 | pages = 269–81 | year = 2004 | pmid = 15515828 | url = http://www.vpci.org.in/upload/Journals/pic130.pdf#page=27 | format = PDF | archive-url = https://web.archive.org/web/20081217024508/http://www.vpci.org.in/upload/Journals/pic130.pdf#page=27 | deadurl = no | archive-date = 2008年12月17日 }}</ref>

<ref name="Charloux">{{cite journal | vauthors = Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H | title = The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma | journal = International Journal of Epidemiology | volume = 26 | issue = 1 | pages = 14–23 | date = February 1997 | pmid = 9126499 | doi = 10.1093/ije/26.1.14 | url = http://ije.oxfordjournals.org/cgi/reprint/26/1/14 | archive-url = https://web.archive.org/web/20081205204700/http://ije.oxfordjournals.org/cgi/reprint/26/1/14 | deadurl = no | archive-date = 2008年12月5日 }}</ref>

<ref name="AUTOREF27">{{Cite book | last=Morgagni | first=Giovanni Battista | name-list-format = vanc | title=De sedibus et causis morborum per anatomen indagatis | year=1761 |ol=24830495M }}</ref>

<ref name="AUTOREF28">{{Cite book | last=Bayle | first=Gaspard-Laurent | name-list-format = vanc | title=Recherches sur la phthisie pulmonaire |place=Paris |language=fr | year=1810 |ol=15355651W }}</ref>

<ref name="Witschi">{{cite journal | vauthors = Witschi H | title = A short history of lung cancer | journal = Toxicological Sciences | volume = 64 | issue = 1 | pages = 4–6 | date = November 2001 | pmid = 11606795 | doi = 10.1093/toxsci/64.1.4 | url = http://toxsci.oxfordjournals.org/cgi/content/full/64/1/4 | archive-url = https://web.archive.org/web/20070309064452/http://toxsci.oxfordjournals.org/cgi/content/full/64/1/4 | deadurl = no | archive-date = 2007年3月9日 }}</ref>

<ref name="AUTOREF29">{{Cite book | author=Adler, I | year=1912 | title=Primary Malignant Growths of the Lungs and Bronchi | place= New York | publisher=Longmans, Green, and Company | oclc=14783544 | ol=24396062M }}, cited in {{cite journal | vauthors = Spiro SG, Silvestri GA | title = One hundred years of lung cancer | journal = American Journal of Respiratory and Critical Care Medicine | volume = 172 | issue = 5 | pages = 523–9 | date = September 2005 | pmid = 15961694 | doi = 10.1164/rccm.200504-531OE }}</ref>

<ref name="Grannis">{{cite web | vauthors = Grannis FW |title=History of cigarette smoking and lung cancer | publisher=smokinglungs.com | url=http://www.smokinglungs.com/cighist.htm | access-date=2007年8月6日 | archive-url = https://web.archive.org/web/20070718174754/http://www.smokinglungs.com/cighist.htm| archive-date = 2007年7月18日}}</ref>

<ref name="Proctor">{{Cite book | vauthors = Proctor R | title=The Nazi War on Cancer | publisher=Princeton University Press | year=2000 | pages=173–246 | isbn=0-691-00196-0 }}</ref>

<ref name="Doll">{{cite journal | vauthors = Doll R, Hill AB | title = Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors | journal = British Medical Journal | volume = 2 | issue = 5001 | pages = 1071–81 | date = November 1956 | pmid = 13364389 | pmc = 2035864 | doi = 10.1136/bmj.2.5001.1071 }}</ref>

<ref name="AUTOREF30">{{cite web | author=US Department of Health Education and Welfare | title=Smoking and health: report of the advisory committee to the Surgeon General of the Public Health Service | location=Washington, DC | publisher=US Government Printing Office | year=1964 | url=http://profiles.nlm.nih.gov/NN/B/B/M/Q/_/nnbbmq.pdf | format=PDF | deadurl=no | archive-url=https://web.archive.org/web/20081217024606/http://profiles.nlm.nih.gov/NN/B/B/M/Q/_/nnbbmq.pdf | archive-date=2008年12月17日 }}</ref>

<ref name="Greaves">{{Cite book | vauthors = Greaves M | title=Cancer: the Evolutionary Legacy | publisher=Oxford University Press | year=2000 | pages=196–197 | isbn=0-19-262835-6 }}</ref>

<ref name="AUTOREF32">{{cite journal | vauthors = Horn L, Johnson DH | title = Evarts A. Graham and the first pneumonectomy for lung cancer | journal = Journal of Clinical Oncology | volume = 26 | issue = 19 | pages = 3268–75 | date = July 2008 | pmid = 18591561 | doi = 10.1200/JCO.2008.16.8260 | url = http://jco.ascopubs.org/cgi/pdf_extract/26/19/3268 }}</ref>

<ref name="Edwards">{{cite journal | vauthors = Edwards AT | title = Carcinoma of the bronchus | journal = Thorax | volume = 1 | issue = 1 | pages = 1–25 | date = March 1946 | pmid = 20986395 | pmc = 1018207 | doi = 10.1136/thx.1.1.1 }}</ref>

<ref name="AUTOREF33">{{cite journal | vauthors = Kabela M | title = [Experience with radical irradiation of bronchial cancer] | language = de | journal = Ceskoslovenska Onkologia | volume = 3 | issue = 2 | pages = 109–15 | year = 1956 | pmid = 13383622 | trans-title = Experience with radical irradiation of bronchial cancer }}</ref>

<ref name="Saunders">{{cite journal | vauthors = Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M | title = Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee | journal = Lancet | volume = 350 | issue = 9072 | pages = 161–5 | date = July 1997 | pmid = 9250182 | doi = 10.1016/S0140-6736(97)06305-8 | publisher = Elsevier }}</ref>

<ref name="AUTOREF34">{{cite journal | vauthors = Lennox SC, Flavell G, Pollock DJ, Thompson VC, Wilkins JL | title = Results of resection for oat-cell carcinoma of the lung | journal = Lancet | volume = 2 | issue = 7575 | pages = 925–7 | date = November 1968 | pmid = 4176258 | doi = 10.1016/S0140-6736(68)91163-X | publisher = Elsevier }}</ref>

<ref name="AUTOREF35">{{cite journal | vauthors = Miller AB, Fox W, Tall R | title = Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus | journal = Lancet | volume = 2 | issue = 7619 | pages = 501–5 | date = September 1969 | pmid = 4184834 | doi = 10.1016/S0140-6736(69)90212-8 | publisher = Elsevier }}</ref>

<ref name="AUTOREF36">{{cite journal | vauthors = Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston AV, Williams CL, Minna JD | title = Intensive chemotherapy of small cell bronchogenic carcinoma | journal = Cancer Treatment Reports | volume = 61 | issue = 3 | pages = 349–54 | year = 1977 | pmid = 194691 }}</ref>

}}

==外部連結==
{{Medical resources
|DiseasesDB = 7616
|ICD10 = {{ICD10|C|33||c|30}}-{{ICD10|C|34||c|30}}
|ICD9 = {{ICD9|162}}
|ICDO =
|OMIM =211980
|MedlinePlus = 007194
|eMedicineSubj = med
|eMedicineTopic = 1333
|eMedicine_mult = {{eMedicine2|med|1336}} {{eMedicine2|emerg|335}} {{eMedicine2|radio|807}} {{eMedicine2|radio|405}} {{eMedicine2|radio|406}}
|MeshID = D002283
}}
{{commons category|Lung cancers}}
* {{dmoz|Health/Conditions_and_Diseases/Cancer/Lung/}}

{{Respiratory tract neoplasia}}

{{Authority control}}

{{DEFAULTSORT:Lung cancer}}
[[Category:肺部肿瘤|*]]
[[Category:吸烟|Category:吸烟]]
{{Featured article}}